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AMPHIPHILIC CYCLOBUTENES AND wherein : 
CYLOBUTANES represents an optionally present double bond ; 
R ' and R are independently selected from the group con 
CROSS - REFERENCE TO RELATED sisting of : H , halo , ORS , and = 0 ; 
APPLICATIONS 5 R² is absent or is an optionally substituted C -C40 alkyl ; 
R * is H or an optionally substituted C - C40 alkyl ; and 
This application is a National Stage Application under 35 Z is selected from the group consisting of : COR® , CO Rº , 
U.S.C. $ 371 and claims the benefit of International Appli NHC ( O ) NR R7 , CONR , OCOR , OR , SR , NR R7 
cation No. PCT / US2013 / 042897 , filed on May 28 , 2013 , and OPO , R ; 
which claims priority to U.S. application Ser . Nos . 61/651 , 10 Rºis H or C -Co alkyl ; 
752 , filed on May 25 , 2012 , and 61 / 702,782 , filed on Sep. R and R ’ are independently H or C -Co alkyl ; 
19 , 2012 , both of the disclosures of which are incorporated wherein the hydrocarbon backbone formed by R * and R3 - Z 
by reference in their entireties herein . is amphiphilic , with the proviso that the compound of Formula ( I ) is not : 
TECHNICAL FIELD 15 
This disclosure relates to amphiphilic compounds con 
taining a cyclobutene or cyclobutane moiety . In some 
embodiments , the compounds are useful for treating infec 
tion by mycobacterium such as Mycobacterium tuberculosis . 20 
Cyclobutene containing compounds are also useful as mono 




Tuberculosis resulting from infection by Mycobacterium 
tuberculosis ( M. tb ) poses a significant disease threat . Based 
on skin test reactivity , it is estimated that one - third of the 
world's population has been exposed , resulting annually in 
approximately nine million cases and 1.4 million deaths 30 
( 2010 data ) ( see Raviglione , M. et al . Lancet 2012 , 379 , 
1902-1913 ) . The current vaccine , M. bovis BCG , yields 
inconsistent protection and can interfere with diagnostic skin 
tests . Although numerous candidate vaccines are being 
tested , their overall safety and efficacy has not been estab- 35 
lished . Although a number of therapeutic agents have been 
developed , current treatment regimens require patients to 
take multiple drugs over a period of months . This , combined 
with significant drug side effects , commonly results in 
patient noncompliance leading to relapses and the emer- 40 
gence of drug resistance ; 3 a high fraction of active cases 
involve multi - drug resistant ( MDR , XDR ) strains . 
SUMMARY 
45 In some embodiments , the compound provided herein can It is believed that much of the hardiness and drug resis 
tance of mycobacteria are due to an unusually thick lipid cell be used in a method for treating a mycobacterial infection in 
wall containing a significant proportion of mycolic acids , a a patient , the method comprising administering to the patient a therapeutically effective amount of a compound of For unique class of C54 - C63 branched - chain fatty acids . A num 
ber of existing treatments for M. tb , exemplified by isoniazid 50 example , a compound provided herein can be used to treat mula ( I ) or a pharmaceutically acceptable salt thereof . For and ethionamide , inhibit mycolic acid biosynthesis . Myco 
bacteria incorporate C16 and C18 fatty acids as biosynthetic a mycobacterial infection such as M. tuberculosis . 
feedstocks . The compounds provided herein mimic these Further provided herein are polymers prepared from a compound of Formula ( IV ) : feedstocks and the uptake of these specifically functional 
ized fatty acids is thought to inhibit downstream mycolic 55 
acid biosynthesis , leading to virulence - attenuating or even 
lethal alterations in the mycobacterial cell wall structure . 
Provided herein are compounds of Formula ( I ) : 
R4 R3 - Z 
60 
R ! R2 or a pharmaceutically acceptable salt thereof , 
wherein : 
R3 is absent or is an optionally substituted C , -C40 alkyl ; 
R4 is H or an optionally substituted CZ - C40 alkyl ; and 
65 Z is selected from the group consisting of : CORE , CO , Rº , 
NHC ( O ) NRØR ?, CONR , OCOR , OR , SR , NRÖR ?, 
and OPOZR® ; 
R4 R3 — Z 
or a pharmaceutically acceptable salt thereof , 
10 
1 
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R $ is H or C , -C6 alkyl ; FIG . 3 shows the minimum inhibitory concentrations 
Rand R7 are independently H or C.-C. alkyl ; ( MICS ) of eleven analogs against M. smeg . ( mc2155 ) and 
wherein the hydrocarbon backbone formed by R4 and R3_Z M. tb ( CDC1551 and H37Rv ) . 
is amphiphilic . FIG . 4 illustrates the cytotoxicity of 1 measured in RAW 
For example , a compound of Formula ( IV ) can be pre- 5 264.7 cells . 
pared by reacting an unsaturated fatty acid or derivative 
DETAILED DESCRIPTION thereof having a backbone comprising at least one carbon 
carbon double bond with dihaloketene to achieve a stereo Definitions specific cycloaddition across the at least one carbon - carbon 
double bond , thereby yielding a cycloketone - containing For the terms “ for example ” and “ such as , ” and gram fatty acid derivative comprising a cycloketone along the matical equivalences thereof , the phrase " and without limi backbone , wherein the cycloketone comprises at least four tation ” is understood to follow unless explicitly stated carbon atoms , with at least two of the at least four carbon otherwise . As used herein , the term “ about ” is meant to atoms being part of the backbone of the cycloketone 15 account for variations due to experimental error . All mea containing fatty acid derivative ; reducing the cycloketone surements reported herein are understood to be modified by containing fatty acid derivative to yield an amphiphilic the term “ about ” , whether or not the term is explicitly used , 
cycloalkene - containing fatty acid derivative having a hydro unless explicitly stated otherwise . As used herein , the sin 
phobic end , a hydrophilic end , and a backbone therebetween gular forms “ a , ” “ an , ” and “ the ” include plural referents 
comprising a cycloalkene , wherein the cycloalkene com- 20 unless the context clearly dictates otherwise . 
prises at least four carbon atoms , with at least two of the four The term “ alkyl ” includes straight - chain alkyl groups 
carbon atoms being part of the backbone of the amphiphilic ( e.g. , methyl , ethyl , propyl , butyl , pentyl , hexyl , heptyl , 
cycloalkene - containing fatty acid derivative . octyl , nonyl , decyl , etc. ) and branched - chain alkyl groups 
In some embodiments , a multiplicity of compounds of ( e.g. , isopropyl , tert - butyl , isobutyl , etc. ) . In certain embodi 
Formula ( IV ) can be polymerized to yield a polymer com- 25 ments , a straight chain or branched chain alkyl has twelve or 
prising carbon - carbon double bonds . In some such embodi fewer carbon atoms in its backbone ( e.g. , C7 - C12 for straight 
ments , the polymerization can further include hydrogenating chain ; C3 - C12 for branched chain ) . The term C , -C12 includes 
the carbon - carbon double bonds of the polymer ; cleaving at alkyl groups containing 1 to 12 carbon atoms . 
least some of the carbon - carbon double bonds in the poly The term “ alkenyl ” includes aliphatic groups that may or 
mer via oxidation to yield monomeric products ; cross- 30 may not be substituted , as described above for alkyls , 
linking the amphiphilic cycloalkene - containing fatty acid containing at least one double bond and at least two carbon 
derivatives via the carbon - carbon double bond in the atoms . For example , the term “ alkenyl ” includes straight 
cycloalkene ; ring - opening metathesis reactions ; aligning the chain alkenyl groups ( e.g. , ethenyl , propenyl , butenyl , pen 
backbones of the multiplicity of the amphiphilic cycloalk tenyl , hexenyl , heptenyl , octenyl , nonenyl , and decenyl ) and 
ene - containing fatty acid derivatives before polymerizing 35 branched - chain alkenyl groups . In certain embodiments , a 
the multiplicity of the amphiphilic cycloalkene - containing straight chain or branched chain alkenyl group has twelve or 
fatty acid derivatives ; polymerizing via click - chemistry ; and fewer carbon atoms in its backbone ( e.g. , C2 - C12 for straight 
mixtures thereof . chain ; C3 - C12 for branched chain ) . The term C2 - C12 includes 
Unless otherwise defined , all technical and scientific alkenyl groups containing 2 to 12 carbon atoms . 
terms used herein have the same meaning as commonly 40 The term " alkynyl ” includes unsaturated aliphatic groups 
understood by one of ordinary skill in the art to which this analogous in length and possible substitution to the alkyls 
invention belongs . Methods and materials are described described above , but which contain at least one triple bond 
herein for use in the present invention ; other , suitable and two carbon atoms . For example , the term “ alkynyl ” 
methods and materials known in the art can also be used . includes straight - chain alkynyl groups ( e.g. , ethynyl , pro 
The materials , methods , and examples are illustrative only 45 pynyl , butynyl , pentynyl , hexynyl , heptynyl , octynyl , nony 
and not intended to be limiting . All publications , patent nyl , and decynyl ) and branched - chain alkynyl groups . In 
applications , patents , sequences , database entries , and other certain embodiments , a straight chain or branched chain 
references mentioned herein are incorporated by reference in alkynyl group has twelve or fewer carbon atoms in its 
their entirety . In case of conflict , the present specification , backbone ( e.g. , C2 - C12 for straight chain ; Cz - C12 for 
including definitions , will control . 50 branched chain ) . The term C2 - C12 includes alkynyl groups 
Other features and advantages of the invention will be containing 2 to 12 carbon atoms . 
apparent from the following detailed description and figures , The term “ alkoxy ” is used in its conventional sense , and 
and from the claims . refers to alkyl groups linked to molecules via an oxygen 
atom . In some embodiments , an alkoxy has twelve or fewer 
DESCRIPTION OF DRAWINGS 55 carbon atoms in its backbone ( e.g. , a C , -C12 alkoxy ) . For 
example , C - C10 , C. - Cg , C.-C. , C. - C4 , C. - Cz , or C.-C. 
FIG . 1 illustrates the thermal stability of cyclobutene 1. y Non - limiting examples of an alkoxy group include methoxy , 
axis is weight in mg for the lower line and heat flow endo ethoxy , propoxy , butoxy , and hexoxy . 
down in mW for top line . The terms “ halo ” or “ halogen ” , used alone or in combi 
FIG . 2 shows 1D ' H NMR spectra of compounds ( A ) 1 60 nation with other terms , refers to fluoro , chloro , bromo and 
and ( B ) 8 that were inspected for evidence of micelle iodo . 
formation ( peak broadening ) by comparing peak widths The term “ haloalkyl ” refers to an alkyl group in which one 
relative to TMSP ( standard ) . Peak widths for compound 1 or more of the hydrogen atoms has been replaced by a 
exhibited potential micelle formation or aggregation over halogen atom . The term “ Cn Cm haloalkyl ” refers to a 
the range of tested concentrations ( highlighted region ) . No 65 Cm Cm alkyl group having n to m carbon atoms , and from 
micelle formation was observed for compound 8 over the at least one up to { 2 ( n to m ) +1 } halogen atoms ,which may 
concentrations of 100 uM , 500 uM , 750 uM , and 1000 uM . either be the same or different . In some embodiments , the 
US 10,538,475 B2 
5 6 
halogen atoms are fluoro atoms . In some embodiments , the NO2 , ORCI , SRal , C ( ORI , C ( O ) NR TROI , C ( O ) Oral , 
haloalkyl group has 1 to 6 or 1 to 4 carbon atoms . Example OCTORb1 , OC ( O ) NRCIRDI , CENREI NRCIRI , NRC 
haloalkyl groups include CF3 , C2F5 , CHF2 , CC13 , CHC12 , ( NREI ) NRCIRI , NRCIRII , NRCIC ( O ) RbI , NRCIC ( O ) 
C2Cl , and the like . In some embodiments , the haloalkyl Oral , NRC C ( O ) NRCRd1 , NRCIS ( O ) RBI , NRC'S ( O ) , Rb1 , 
group is a fluoroalkyl group . 5 NRCS ( O ) 2NRCIRII , S ( O ) R51 , S ( O ) NRCIRI , S ( O ) , Rb1 and The term “ haloalkoxy ” , employed alone or in combina S ( O ) NRORI tion with other terms , refers to a group of formula 0 each Cyl is independently C6-10 aryl , C3.10 carbocyclyl , 
haloalkyl , wherein the haloalkyl group is as defined above . 5-10 membered heteroaryl or 4-10 membered heterocyclyl , The term “ CnCm haloalkoxy ” refers to a haloalkoxy each of which is unsubstituted or substituted by 1 , 2 , 3 , 4 or group , the haloalkyl group of which has n to m carbons . 10 5 substituents independently selected from C1-6 alkyl , C2-6 Example haloalkoxy groups include trifluoromethoxy and alkenyl , C2-6 alkynyl , halo , CN , NO , ORI , SRI , C ( ORI the like . In some embodiments , the haloalkoxy group has 1 CONRCIRd , C ( O ) ORT , OCOR , OC ( O ) NRC?Rd , to 6 , 1 to 4 , or 1 to 3 carbon atoms . CENRI )NRCIRI NRCCNR ) NRCIRI NR RI , The term “ amino ” refers to a group of formula -NH2 . NR - C ( O ) R51 , NRCIC ( O ) ORI ,NRCIC ( O ) NRCRAI , NR IS The term “ carbamyl ” refers to a group of formula - C ( O ) 15 
NH2 ( O ) RI , NRCIS ( O ) , R01 , NRCS ( O ) 2NRCIRd !, ( O ) RbI , S ( O ) NRCIRI , S ( O ) , Rbí , s ( 0 ) NRCIRái and oxo ; The term “ carbonyl ” , employed alone or in combination each Ral , Rbi , Rei , R1 , is independently selected from H , with other terms , refers to a CEO ) — group , which also 
may be written as C ( O ) . C1-6 alkyl , C1-4 haloalkyl , C2-6 alkenyl , C2-6 alkynyl , C6-10 
The term “ oxo ” refers to oxygen as a divalent substituent , 20 aryl , C3-10 carbocyclyl , 5-10 membered heteroaryl , 4-10 
forming a carbonyl group , or attached to a heteroatom membered heterocyclyl , C6-10 aryl - C - 4 alkyl , C3-10 carbo 
forming a sulfoxide or sulfone group , or an N - oxide group . cyclyl - C1-4 alkyl , ( 5-10 membered heteroaryl ) -C1-4 alkyl or 
The term " aromatic ” refers to a carbocycle or heterocycle ( 4-10 membered heterocyclyl ) -C -4 alkyl , wherein said C1-6 
having one or more polyunsaturated rings having aromatic alkyl , C. , alkenyl , C2 . alkynyl , C6-10 aryl , C3.10 carbocy 
character ( i.e. , having ( 4n + 2 ) delocalized or ( pi ) electrons 25 clyl , 5-10 membered heteroaryl , 4-10 membered heterocy 
where n is an integer ) . clyl , C6-10 aryl - C1-4 alkyl , C3-10 carbocyclyl - C1-4 alkyl , 
The term " carbocyclyl ” includes a cyclic aliphatic group ( 5-10 membered heteroaryl ) -C1-4 alkyl and ( 4-10 membered 
which may be saturated or unsaturated . For example , car heterocyclyl ) -C1-4 alkyl is optionally substituted with 1 , 2 , 3 , 
bocyclyl groups include cyclopropyl , cyclopentyl , cyclo 4 , or 5 substituents independently selected from C1-4 alkyl , 
C ( O ) hexyl , cycloheptyl , and cyclooctyl . In some embodiments , 30 C1- haloalkyl , halo , CN , OR24 , SR44 , C ( O ) R64 , NRCARd4 , COORA4 , OC ( O ) R54 , OC ( O ) NRCANR44 , carbocyclyls have from 3-8 carbon atoms in their ring NR NR 14 NRCAC ( O ) R 64 , NR 4C ( O ) NR 4Rd4 NR 4C ( 0 ) structure , for example , they can have 3 , 4 , 5 or 6 carbons in 
the ring structure . ORC4 , Ce = NRe4 ) NRAR44 , NRCACE = NR®4 ) NRARd4 , S ( O ) 
In general , the term “ aryl ” includes groups , including 5 Rb4 , S ( O ) NRC4R04 , S ( O ) , Rb4 , NRC + S ( O ) _Rb4 , NRAS ( O ) 2 
and 6 - membered single - ring aromatic groups , such as ben- 35 and S ( O ) 2NRC4Rd4 ; 
zene and phenyl . Furthermore , the term “ aryl ” includes each Ra4 , Rb4 , RC4 and Rd4 is independently selected from 
multicyclic aryl groups , e.g. , tricyclic , bicyclic , such as H , C - 4 alkyl , C -4 haloalkyl , C2-4 alkenyl and C2-4 alkynyl , 
naphthalene and anthracene . wherein said C1-4 alkyl , C2-4 alkenyl , and C2-4 alkynyl , is 
The term “ heteroaryl ” includes groups , including 5- and optionally substituted with 1 , 2 , or 3 substituents indepen 
6 - membered single - ring aromatic groups , that have from 40 dently selected from OH , CN , amino , halo , C1-4 alkyl , C1-4 
one to four heteroatoms , for example , pyrrole , furan , thio alkoxy , C1-4 alkylthio , C1-4 alkylamino , di ( C1-4 alkyl ) amino , 
phene , thiazole , isothiaozole , imidazole , triazole , tetrazole , C - 4 haloalkyl , and C - 4 haloalkoxy . 
pyrazole , oxazole , isooxazole , pyridine , pyraiine , Where substituent groups are specified by their conven 
pyridazine , and pyrimidine , and the like . Furthermore , the tional chemical formulas , written from left to right , they 
term " heteroaryl ” includes multicyclic heteroaryl groups , 45 equally encompass the chemically identical substituents that would result from writing the structure from right to left , for e.g. , tricyclic , bicyclic , such as benzoxazole , benzodiox 
azole , benzothiazole , benzoimidazole , benzothiophene , example , CH2O– is equivalent to t OCH2— . In some methylenedioxyphenyl , quinoline , isoquinoline , napthyri embodiments , one or more substituents can be a group 
dine , indole , benzofuran , purine , benzofuran , quinazoline , reactive with a biologically active molecule or a detectable 
deazapurine , indazole , or indolizine . agent . 
The term " heterocyclyl ” includes non - aromatic groups , As used herein , chemical structures which contain one or 
including but not limited to , 3- to 10 - membered single or more stereocenters depicted with dashed and bold bonds 
multiple non - aromatic rings having one to five heteroatoms , ( i.e. , 1 ) are meant to indicate absolute stereochemistry of 
for example , oxetane , piperazine , pyrrolidine , piperidine , or the stereocenter ( s ) present in the chemical structure . As used 
homopiperazine . 55 herein , bonds symbolized by a simple line do not indicate a 
The term “ substituted ” means that an atom or group of stereo - preference . Unless otherwise indicated , chemical 
atoms replaces hydrogen as a “ substituent ” attached to structures , which include one or more stereocenters , illus 
another group . For aryl and heteroaryl groups , the term trated herein without indicating absolute or relative stereo 
“ substituted ” , unless otherwise indicated , refers to any level chemistry encompass all possible stereoisomeric forms of 
of substitution , namely mono , di , tri , tetra , or penta substi- 60 the compound ( e.g. , diastereomers , enantiomers ) and mix 
tution , where such substitution is permitted . The substituents tures thereof ( e.g. , racemic mixtures ) . Structures with a 
are independently selected , and substitution may be at any single bold or dashed line , and at least one additional simple 
chemically accessible position . In some cases , two sites of line , encompass a single enantiomeric series of all possible 
substitution may come together to form a 3-10 membered diastereomers . 
carbocyclyl or heterocyclyl ring . Resolution of racemic mixtures of compounds can be 
Substituents include , but are not limited to , Cy ?, C1-6 carried out by any of numerous methods known in the art . 
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using a chiral resolving acid which is an optically active , base or acid in water or in an organic solvent , or in a mixture 
salt - forming organic acid . Suitable resolving agents for of the two ; in some embodiments , a non - aqueous media like 
fractional recrystallization methods are , for example , opti ether , ethyl acetate , alcohols ( e.g. , methanol , ethanol , iso 
cally active acids , such as the D and L forms of tartaric acid , propanol , or butanol ) or acetonitrile ( ACN ) can be used . 
diacetyltartaric acid , dibenzoyltartaric acid , mandelic acid , 5 Lists of suitable salts are found in Remington's Pharmaceu 
malic acid , lactic acid , or the various optically active cam tical Sciences , 17th ed . , Mack Publishing Company , Easton , 
phorsulfonic acids such as camphorsulfonic acid . Other Pa . , 1985 , p . 1418 and Journal of Pharmaceutical Science , 
resolving agents suitable for fractional crystallization meth 66 , 2 ( 1977 ) . Conventional methods for preparing salts are 
ods include stereoisomerically pure forms of methylben described , for example , in Handbook of Pharmaceutical 
zylamine ( e.g. , S and R forms , or diastereomerically pure 10 Salts : Properties , Selection , and Use , Wiley - VCH , 2002 . 
forms ) , 2 - phenylglycinol , norephedrine , ephedrine , N - meth The term “ essentially pure ” refers to chemical purity of a 
ylephedrine , cyclohexylethylamine , 1,2 - diaminocyclo compound provided herein that may be substantially or 
hexane , and the like . essentially free of other components which normally accom 
Resolution of racemic mixtures can also be carried out by pany or interact with the compound prior to purification . By 
elution on a column packed with an optically active resolv- 15 way of example only , a compound may be “ essentially pure ” 
ing agent ( e.g. , dinitrobenzoylphenylglycine ) . Suitable elu when the preparation of the compound contains less than 
tion solvent compositions can be determined by one skilled about 30 % , less than about 25 % , less than about 20 % , less 
in the art . than about 15 % , less than about 10 % , less than about 5 % , 
The phrase “ pharmaceutically acceptable ” is employed less than about 4 % , less than about 3 % , less than about 2 % , 
herein to refer to those compounds , materials , compositions , 20 or less than about 1 % ( by dry weight ) of contaminating 
and / or dosage forms which are , within the scope of sound components . Thus , an “ essentially pure ” compound may 
medical judgment , suitable for use in contact with the tissues have a purity level of about 70 % , about 75 % , about 80 % , 
of human beings and animals without excessive toxicity , about 85 % , about 90 % , about 95 % , about 96 % , about 97 % , 
irritation , allergic response , or other problem or complica about 98 % , about 99 % or greater . For the purposes of this 
tion , commensurate with a reasonable benefit / risk ratio . 25 document , preparations of functionalized polymers or con 
The term “ salt ” includes any ionic form of a compound jugates differing only in the length of their polymer chain are 
and one or more counter - ionic species ( cations and / or considered to be essentially pure . An essentially pure com 
anions ) . Salts also include zwitterionic compounds ( i.e. , a pound may be obtained using chromatographic purification 
molecule containing one more cationic and anionic species , methods . 
e.g. , zwitterionic amino acids ) . Counter ions present in a salt 30 As used herein , “ amphiphilic ” or “ amphiphile ” refers to a 
can include any cationic , anionic , or zwitterionic species . chemical compound possessing regions of very different 
Exemplary anions include , but are not limited to : chloride , properties in terms of preferred solvation or association with 
de , nit te , sulfate , bisulfate , sulfite , bisulfite , a liquid interface or a solid surface . The most common 
phosphate , acid phosphate , perchlorate , chlorate , chlorite , examples of amphiphiles possess both hydrophilic ( water 
hypochlorite , periodate , iodate , iodite , hypoiodite , carbon- 35 loving , polar ) and lipid ( fat - loving , non - polar ) properties . 
ate , bicarbonate , isonicotinate , acetate , trichloroacetate , tri Generally , amphiphilic compounds herein have a polar 
fluoroacetate , lactate , salicylate , citrate , tartrate , pantothen region on one half or terminal portion of the compound and 
ate , bitartrate , ascorbate , succinate , maleate , gentisinate , a non - polar region at the opposite half or terminal portion of 
fumarate , gluconate , glucaronate , saccharate , formate , ben the compound . Fatty acids , triglycerides , and derivatives 
zoate , glutamate , methanesulfonate , trifluoromethanesul- 40 thereof are examples of amphiphilic compounds . An 
fonate , ethanesulfonate , benzenesulfonate , p - toluenesul example of another class of amphiphiles are molecules 
fonate , p - trifluoromethylbenzenesulfonate , hydroxide , containing either a hydrophobic or hydrophiic region on one 
aluminates , and borates . Exemplary cations include , but are half or terminal portion of the molecule and a thiol or similar 
not limited to : monovalent alkali metal cations , such as functional group possessing high affinity for a metal on the 
lithium , sodium , potassium , and cesium , and divalent alka- 45 other half or terminus . 
line earth metals , such as beryllium , magnesium , calcium , “ Fatty acid derivatives ” as used herein refer to com 
strontium , and barium . Also included are transition metal pounds having a fatty acid hydrocarbon backbone , but 
cations , such as gold , silver , copper and zinc , as well as which may be optionally substituted as provided herein . In 
non - metal cations , such as ammonium salts . addition , a fatty acid derivative may have the carboxylic acid 
Also provided herein are pharmaceutically acceptable 50 functional group replaced with another reactive group , for 
salts of the compounds described herein . As used herein , example , a hydroxyl group , an ester group , an aldehyde 
" pharmaceutically acceptable salts ” refers to derivatives of group , a carboxyl group , a sulfhydryl group , an amine 
the disclosed compounds wherein the parent compound is group , an amide group , a carbamide group , or a phosphate 
modified by converting an existing acid or base moiety to its group . 
salt . Examples of pharmaceutically acceptable salts include , 55 A “ therapeutically effective amount ” of a compound with 
but are not limited to , mineral or organic acid salts of basic respect to the subject method of treatment , refers to an 
residues such as amines ; alkali or organic salts of acidic amount of the compound ( s ) in a preparation which , when 
residues such as carboxylic acids , and the like . The phar administered as part of a desired dosage regimen ( to a 
maceutically acceptable salts of the compounds provided patient , e.g. , a human ) alleviates a symptom , ameliorates a 
herein include the conventional non - toxic salts of the parent 60 condition , or slows the onset of disease conditions according 
compound formed , for example , from non - toxic inorganic or to clinically acceptable standards for the disorder or condi 
organic acids . The pharmaceutically acceptable salts of the tion to be treated or the cosmetic purpose , e.g. , at a reason 
compounds provided herein can be synthesized from the able benefit / risk ratio applicable to any medical treatment . 
parent compound which contains a basic or acidic moiety by As used herein , the term “ treating ” or “ treatment ” 
conventional chemical methods . Generally , such salts can be 65 includes reversing , reducing , or arresting the symptoms , 
prepared by reacting the free acid or base forms of these clinical signs , and underlying pathology of a condition in 
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Antimicrobial Agents In some embodiments , at least one of R² or R4 is a C7 - C40 
Provided herein are amphiphilic compounds containing a alkyl . For example , if R * is H , then R ’ is a C , -C40 alkyl ( e.g. , 
cyclobutane or cyclobutene moiety . For example , amphiphi Cs - C20 alkyl , C16C30 alkyl , and C2 - C , alkyl ) , or if R3 is 
lic acids , alcohols , esters , thiols , amides , or related groups absent , then R * is C , -C40 alkyl ( e.g. , C5 - C20 alkyl , C10C30 
incorporating within their backbone a four - membered ring 5 alkyl , and C2 - C , alkyl ) . In some embodiments , R ’ is a 
carbocycle ( cyclobutane , cyclobutene , cyclobutanone , or C7 - C10 alkyl . For example , Rº can be a C , alkyl . In some 
substituted derivatives ) . embodiments , R4 is a C , -C10 alkyl . For example , R * can be 
A compound provided herein can include a compound of a Cg alkyl . In some embodiments , R4 is H. R3 and R4 can be 
Formula ( I ) : independently optionally substituted . For example , substitu 
ents include , but are not limited to , Cy ?, C1-6 alkyl , C2-6 
alkenyl , C2-6 alkynyl , halo , C1-6 haloalkyl , CN , NO2 , ORal , 
R ! R2 SR " , CORT , C ( O ) NRC?R " , C ( O ) ORCI , OC ( O ) R51 , 
OC ( O ) NRCIRDI , CENRI ) NRCIRI , ENRE  Rd , NR CENRel ) 
NRCIRI , NRC'RI , NRCIC ( O ) R1 ,NRCIC ( O ) ORI , NRC 
( O ) NRCIRPI , NR IS ( ORI , NRCS ( O ) , R51 , NRC'S ( O ) 2 R4 R3 - Z NRCIR I , S ( O ) RI , S ( O ) NRCIR ( I , S ( O ) , R0l and S ( O ) , 
NRCIRDI . 
or a pharmaceutically acceptable salt thereof , each Cyl is independently C6-10 aryl , C3-10 carbocyclyl , 
wherein : 20 5-10 membered heteroaryl or 4-10 membered heterocyclyl , 
represents an optionally present double bond ; each of which is unsubstituted or substituted by 1 , 2 , 3 , 4 or 
R1 and R2 are independently selected from the group con 5 substituents independently selected from C1-6 alkyl , C2-6 
sisting of : H , halo , OR , and = 0 ; alkenyl , C2 - alkynyl , halo , CN , NO , ORCI , SRal , C ( O ) Rhi 
R is absent or is an optionally substituted C , -C40 alkyl ; C ( O ) NRCROI , COOR , OCOR , OC ( O ) NRCÍrdi , 
R * is H or an optionally substituted C , -C40 alkyl ; and 25 CCNRel ) NRclRd , NRCC_NR® NRclRdì , NRC Rd . 
Z is selected from the group consisting of : CORO , COR " , NRICOR61 , NRC COORI , NR - C ( O ) NRIRI , NR'S 
NHC ( O ) NROR ” , CONR ” , OCOR , OR® , SR “ , NRÓR ?, ( O ) R51 , NRCIS ( O ) , Rb1 , NRCIS ( O ) 2NRCIRI , S ( O ) R51 , S ( O ) 
and OPO , R ; NRCIR I , S ( O ) , R1 , S ( O ) , NRCIR and oxo ; 
Ris H or C.-C. alkyl ; each Ral , Roí , Rei , Rdi , is independently selected from H , 
R and R7 are independently H or C , -C . alkyl ; 30 C1-6 alkyl , C1-4 haloalkyl , C2-6 alkenyl , C2-6 alkynyl , C6-10 
wherein the hydrocarbon backbone formed by R4 and R3 - Z aryl , C3-10 carbocyclyl , 5-10 membered heteroaryl , 4-10 
is amphiphilic membered heterocyclyl , C6-10 aryl - C1-4 alkyl , C3-10 carbo 
In some embodiments , the compound of Formula ( I ) is cyclyl - C1-4 alkyl , ( 5-10 membered heteroaryl ) -C1-4 alkyl or ( 4-10 membered heterocyclyl ) -C1-4 alkyl , wherein said C1-6 
35 alkyl , C2-6 alkenyl , C2-6 alkynyl , C6-10 aryl , C3-10 carbocy 
clyl , 5-10 membered heteroaryl , 4-10 membered heterocy 
clyl , C6-10 aryl - C14 alkyl , C3-10 carbocyclyl - C1-4 alkyl , 
( 5-10 membered heteroaryl ) -C1-4 alkyl and ( 4-10 membered 
heterocyclyl ) -C1-4 alkyl is optionally substituted with 1 , 2 , 3 , 
40 4 , or 5 substituents independently selected from C1-4 alkyl , 
C - 4 haloalkyl , halo , CN , ORC4 , SR44 , C ( O ) R 64 , C ( O ) 
NR 4R04 , C ( O ) OR4 , OC ( O ) R64 , OC ( O ) NR 4Rd4 , NRC4R04 , 
NRC4C ( O ) Rb4 NRCAC ( C ( O ) NRCARd4 , NRC4C ( O ) OR24 , 
CENR ) NRC4R14 , NRACENR®4 ) NR 4R04 , SO64 , 
45 S ( O ) NRC4R04 , S ( O ) Rb4 , NRC4S ( O ) 2Rb4 , NRC4S ( O ) 2 
NRC4Rd4 and S ( O ) 2NRCARd4 ; 
each R24 , Rb4 , RCA and Rd4 is independently selected from 
H , C - 4 alkyl , C -4 haloalkyl , C2-4 alkenyl and C2-4 alkynyl , 
wherein said C.4 alkyl , C2-4 alkenyl , and C2.4 alkynyl , is 
50 optionally substituted with 1 , 2 , or 3 substituents indepen 
dently selected from OH , CN , amino , halo , C1-4 alkyl , C1-4 
alkoxy , C1-4 alkylthio , C1-4 alkylamino , di ( C1-4 alkyl ) amino , 
C1-4 haloalkyl , and C1-4 haloalkoxy . 
In some embodiments , the substituents can be selected 
55 from the group consisting of an alkyl , a halogen , a hydroxyl , 
an alkoxyl , a carbonyl ( such as a carboxyl , an alkoxycar 
bonyl , a formyl , or an acyl ) , a thiocarbonyl ( such as a 
thioester , a thioacetate , or a thioformate ) , an alkoxyl , a 
phosphoryl , a phosphate , a phosphonate , a phosphinate , an 
60 amino , an amido , an amidine , an imine , a cyano , a nitro , an 
azido , a suithydryl , an alkylthio , a sulfate , a sulfonate , a 
sulfamoyl , a sulfonamido , a sulfonyl , a carbocyclyl , a het 
erocyclyl , an aralkyl , a heteroaralkyl , or an aromatic or 
heteroaromatic moiety . 
In some embodiments , Z is COR® . 
In some embodiments , R ' and R are independently A compound provided herein can be selected from the 









R4 R3—2 R4 
?? . 
R3 — Z R4 R3—2 
OH 
( CH2 ) 7CO2H ( CH2 ) 7CO2H 
10 R4 R3—2 R4 R3 - Z R4 R3—2 ( CH2 ) 7CO2H ( CH2 ) 7CO2H 
or a pharmaceutically acceptable salt thereof . 
In some embodiments , a compound provided herein can 
be selected from the group consisting of : R4 R3 — Z R4 R3 — Z 15 
or a pharmaceutically acceptable salt thereof , wherein R3 , 
R4 and Z are as described previously . 
In some embodiments , a compound provided herein is a 20 
compound of Formula ( II ) : A C4H8 ( CH2 )7CO2H C4H8 ( CH2 ) 7CO2H 
R R2 C3H8 alloon ( CH2 ) 7CO2H CgHj8 ( CH2 ) 7C02H 
25 
Polls R3 - Z 
( CH2 ) 7CO2H C8H8 C8H8 
?? . 
( CH2 )7CO2H 
OH 30 or a pharmaceutically acceptable salt thereof , wherein R ' , 
R ?, R3 , R4 and Z are as described previously . In some 
embodiments , a compound provided herein is a compound 
of Formula ( III ) : C8H18 ( CH2 ) 7CO2H C8H18 ( CH2 ) 7C02H 
O 35 
R ! R2 
C3H18 ( CH2 ) 7CO2H C3H18 ( CH2 ) 7CO2H 
R4 R3 — Z 40 
CgHì8 ll . ( CH2 ) 7CO2H 
HO 
C3H18 
or a pharmaceutically acceptable salt thereof , wherein R ' , 
R2 , R3 , R4 and Z are as described previously . 
Non - limiting examples of a compound provided herein 45 
includes : 
( CH2 ) 7CO2H 
( CH2 ) 7C02H ( CH2 ) 7C02H 
50 
C3H18 ( CH2 ) 7CO2H C8H18 ( CH2 ) 7CO2H 
( CH2 ) 7CO2H ( CH2 ) 7CO2H 
55 
C3H18 ( CH2 ) 7CO2H C8H18 
?? . 
( CH2 )7CO2H 
OH 
C8H18 ( CH2 ) 7CO2H C8H18 ( CH2 ) 7CO2H 
Ci 
or a pharmaceutically acceptable salt thereof . 
Pharmaceutical Compositions and Dosage Forms 
When employed as pharmaceuticals , the compounds pro 
vided herein can be administered in the form of pharma 
60 ceutical compositions . These compositions can be prepared 
in a manner well known in the pharmaceutical art , and can 
be administered by a variety of routes , depending upon 
whether local or systemic treatment is desired and upon the 
area to be treated . Administration may be topical ( including 
65 transdermal , epidermal , ophthalmic and to mucous mem 
branes including intranasal , vaginal and rectal delivery ) , 
pulmonary ( e.g. , by inhalation or insufflation of powders or 
X C3H8 ( CH2 ) 7CO2H C3H8 ( CH2 ) 7C02H 
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aerosols , including by nebulizer ; intratracheal or intranasal ) , can be readily subdivided into equally effective unit dosage 
oral or parenteral . Parenteral administration includes intra forms such as tablets , pills and capsules . This solid prefor 
venous , intraarterial , subcutaneous , intraperitoneal , intra mulation is then subdivided into unit dosage forms of the 
muscular or injection or infusion ; or intracranial , e.g. , type described above containing from , for example , about 
intrathecal or intraventricular , administration . Parenteral 5 0.1 to about 1000 mg of the active ingredient provided 
administration can be in the form of a single bolus dose , or herein . 
may be , for example , by a continuous perfusion pump . The tablets or pills provided herein can be coated or 
Pharmaceutical compositions and formulations for topical otherwise compounded to provide a dosage form affording 
administration may include transdermal patches , ointments , the advantage of prolonged action . For example , the tablet or 
lotions , creams , gels , drops , suppositories , sprays , liquids 10 pill can comprise an inner dosage and an outer dosage 
and powders . Conventional pharmaceutical carriers , aque component , the latter being in the form of an envelope over 
ous , powder or oily bases , thickeners and the like may be the former . The two components can be separated by an 
necessary or desirable . enteric layer which serves to resist disintegration in the 
This disclosure also provides pharmaceutical composi stomach and permit the inner component to pass intact into 
tions which contain , as the active ingredient , a compound 15 the duodenum or to be delayed in release . A variety of 
provided herein or a pharmaceutically acceptable salt materials can be used for such enteric layers or coatings , 
thereof , in combination with one or more pharmaceutically such materials including a number of polymeric acids and 
acceptable carriers ( excipients ) . In some embodiments , the mixtures of polymeric acids with such materials as shellac , 
composition is suitable for topical administration . In making cetyl alcohol , and cellulose acetate . 
the compositions provided herein , the active ingredient is 20 The liquid forms in which the compounds and composi 
typically mixed with an excipient , diluted by an excipient or tions provided herein can be incorporated for administration 
enclosed within such a carrier in the form of , for example , orally or by injection include aqueous solutions , suitably 
a capsule , sachet , paper , or other container . When the flavored syrups , aqueous or oil suspensions , and flavored 
excipient serves as a diluent , it can be a solid , semi - solid , or emulsions with edible oils such as cottonseed oil , sesame oil , 
liquid material , which acts as a vehicle , carrier or medium 25 coconut oil , or peanut oil , as well as elixirs and similar 
for the active ingredient . Thus , the compositions can be in pharmaceutical vehicles . 
the form of tablets , pills , powders , lozenges , sachets , In some embodiments , the compounds provided herein 
cachets , elixirs , suspensions , emulsions , solutions , syrups , are for nulated for intravenous administration . Pharmaceu 
aerosols ( as a solid or in a liquid medium ) , ointments tical compositions suitable for injectable use can include 
containing , for example , up to 10 % by weight of the active 30 sterile aqueous solutions ( where water soluble ) or disper 
compound , soft and hard gelatin capsules , suppositories , sions and sterile powders for the extemporaneous prepara 
sterile injectable solutions , and sterile packaged powders . tion of sterile injectable solutions or dispersion . For intra 
In preparing a formulation , an active compound can be adminis suitable carriers include 
milled to provide the appropriate particle size prior to physiological saline , bacteriostatic water , Cremophor ELTM 
combining with the other ingredients . If an active compound 35 ( BASF , Parsippany , N.J. ) or phosphate buffered saline 
is substantially insoluble , it can be milled to a particle size ( PBS ) . In all cases , the composition must be sterile and 
of less than 200 mesh . If an active compound is substantially should be fluid to the extent that easy syringability exists . It 
water soluble , the particle size can be adjusted by milling to should be stable under the conditions of manufacture and 
provide a substantially uniform distribution in the formula storage and must be preserved against the contaminating 
tion , e.g. about 40 mesh . 40 action of microorganisms such as bacteria and fungi . The 
The compounds provided herein may be milled using carrier can be a solvent or dispersion medium containing , for 
known milling procedures such as wet milling to obtain a example , water , ethanol , polyol ( for example , glycerol , 
particle size appropriate for tablet formation and for other propylene glycol , and liquid polyethylene glycol , and the 
formulation types . Finely divided ( nanoparticulate ) prepa like ) , and suitable mixtures thereof . The proper fluidity can 
rations of the compounds provided herein can be prepared 45 be maintained , for example , by the use of a coating such as 
by processes known in the art , e.g. , see International App . lecithin , by the maintenance of the required particle size in 
No. WO 2002/000196 . the case of dispersion and by the use of surfactants . Pre 
Some examples of suitable excipients include lactose , vention of the action of microorganisms can be achieved by 
dextrose , sucrose , sorbitol , mannitol , starches , gum acacia , various antibacterial and antifungal agents , for example , 
calcium phosphate , alginates , tragacanth , gelatin , calcium 50 parabens , chlorobutanol , phenol , ascorbic acid , thimerosal , 
silicate , microcrystalline cellulose , polyvinylpyrrolidone , and the like . In many cases , it will be preferable to include 
cellulose , water , syrup , and methyl cellulose . The formula isotonic agents , for example , sugars , polyalcohols such as 
tions can additionally include : lubricating agents such as mannitol , sorbitol , sodium chloride in the composition . 
talc , magnesium stearate , and mineral oil ; wetting agents ; Prolonged absorption of the injectable compositions can be 
emulsifying and suspending agents ; preserving agents such 55 brought about by including in the composition an agent that 
as methyl- and propylhydroxy - benzoates ; sweetening delays absorption , for example , aluminum monostearate and 
agents ; and flavoring agents . The compositions provided gelatin . 
herein can be formulated so as to provide quick , sustained or Sterile injectable solutions can be prepared by incorpo 
delayed release of the active ingredient after administration rating the active compound in the required amount in an 
to the patient by employing procedures known in the art . 60 appropriate solvent with one or a combination of ingredients 
For preparing solid compositions such as tablets , the enumerated above , as required , followed by filter steriliza 
principal active ingredient is mixed with a pharmaceutical tion . Generally , dispersions are prepared by incorporating 
excipient to form a solid preformulation composition con the active compound into a sterile vehicle , which contains a 
taining a homogeneous mixture of a compound provided basic dispersion medium and the required other ingredients 
herein . When referring to these preformulation compositions 65 from those enumerated above . In the case of sterile powders 
as homogeneous , the active ingredient is typically dispersed for the preparation of sterile injectable solutions , the pre 
evenly throughout the composition so that the composition ferred methods of preparation are vacuum drying and freeze 
venous 
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drying , which yield a powder of the active ingredient plus discrete units suitable as unitary dosages for human subjects 
any additional desired ingredient from a previously sterile and other mammals , each unit containing a predetermined 
filtered solution thereof . quantity of active material calculated to produce the desired 
Compositions for inhalation or insufflation include solu therapeutic effect , in association with a suitable pharmaceu 
tions and suspensions in pharmaceutically acceptable , aque- 5 tical excipient . 
ous or organic solvents , or mixtures thereof , and powders . In some embodiments , the compositions provided herein 
The liquid or solid compositions may contain suitable phar contain from about 5 to about 50 mg of the active ingredient . 
maceutically acceptable excipients as described supra . In One having ordinary skill in the art will appreciate that this 
some embodiments , the compositions are administered by embodies compositions containing about 5 to about 10 , 
the oral or nasal respiratory route for local or systemic effect . 10 about 10 to about 15 , about 15 to about 20 , about 20 to about 
Compositions can be nebulized by use of inert gases . Nebu 25 , about 25 to about 30 , about 30 to about 35 , about 35 to 
lized solutions may be breathed directly from the nebulizing about 40 , about 40 to about 45 , or about 45 to about 50 mg 
device or the nebulizing device can be attached to a face of the active ingredient . 
mask , tent , or intermittent positive pressure breathing In some embodiments , the compositions provided herein 
machine . Solution , suspension , or powder compositions can 15 contain from about 50 to about 500 mg of the active 
be administered orally or nasally from devices which deliver ingredient . One having ordinary skill in the art will appre 
the formulation in an appropriate manner . ciate that this embodies compositions containing about 50 to 
Topical formulations can contain one or more conven about 100 , about 100 to about 150 , about 150 to about 200 , 
tional carriers . In some embodiments , ointments can contain about 200 to about 250 , about 250 to about 300 , about 350 
water and one or more hydrophobic carriers selected from , 20 to about 400 , or about 450 to about 500 mg of the active 
for example , liquid paraffin , polyoxyethylene alkyl ether , ingredient . 
propylene glycol , white Vaseline , and the like . Carrier In some embodiments , the compositions provided herein 
compositions of creams can be based on water in combina contain from about 500 to about 1000 mg of the active 
tion with glycerol and one or more other components , e.g. ingredient . One having ordinary skill in the art will appre 
glycerinemonostearate , PEG - glycerinemonostearate and 25 ciate that this embodies compositions containing about 500 
cetylstearyl alcohol . Gels can be formulated using isopropyl to about 550 , about 550 to about 600 , about 600 to about 
alcohol and water , suitably in combination with other com 650 , about 650 to about 700 , about 700 to about 750 , about 
ponents such as , for example , glycerol , hydroxyethyl cellu 750 to about 800 , about 800 to about 850 , about 850 to about 
lose , and the like . In some embodiments , topical formula 900 , about 900 to about 950 , or about 950 to about 1000 mg 
tions contain at least about 0.1 , at least about 0.25 , at least 30 of the active ingredient . 
about 0.5 , at least about 1 , at least about 2 , or at least about Similar dosages may be used of the compounds described 
5 wt % of the compound provided herein . The topical herein in the methods and uses provided herein . 
formulations can be suitably packaged in tubes of , for The active compound can be effective over a wide dosage 
example , 100 g which are optionally associated with instruc range and is generally administered in a pharmaceutically 
tions for the treatment of the select indication . 35 effective amount . It will be understood , however , that the 
In one embodiment , the compounds provided herein are amount of the compound actually administered will usually 
prepared with carriers that will protect the compounds be determined by a physician , according to the relevant 
against rapid elimination from the body , such as a controlled circumstances , including the condition to be treated , the 
release formulation , including implants and microencapsu chosen route of administration , the actual compound admin 
lated delivery systems . Biodegradable , biocompatible poly- 40 istered , the age , weight , and response of the individual 
mers can be used , such as ethylene vinyl acetate , polyan patient , the severity of the patient's symptoms , and the like . 
hydrides , polyglycolic acid , collagen , polyorthoesters , and The amount of compound or composition administered to 
polylactic acid . Such formulations can be prepared using a patient will vary depending upon what is being adminis 
standard techniques , or obtained commercially , e.g. , from tered , the purpose of the administration , such as prophylaxis 
Alza Corporation and Nova Pharmaceuticals , Inc. Lipo- 45 or therapy , the state of the patient , the manner of adminis 
somal suspensions ( including liposomes targeted to selected tration , and the like . In therapeutic applications , composi 
cells with monoclonal antibodies to cellular antigens ) can tions can be administered to a patient already suffering from 
also be used as pharmaceutically acceptable carriers . These a disease in an amount sufficient to cure or at least partially 
can be prepared according to methods known to those arrest the symptoms of the disease and its complications . 
skilled in the art , for example , as described in U.S. Pat . No. 50 Effective doses will depend on the disease condition being 
4,522,811 . treated as well as by the judgment of the attending clinician 
The compositions administered to a patient can be in the depending upon factors such as the severity of the disease , 
form of pharmaceutical compositions described above . the age , weight and general condition of the patient , and the 
These compositions can be sterilized by conventional ster like . 
ilization techniques , or may be sterile filtered . Aqueous 55 The therapeutic dosage of a compound provided herein 
solutions can be packaged for use as is , or lyophilized , the can vary according to , for example , the particular use for 
lyophilized preparation being combined with a sterile aque which the treatment is made , the manner of administration 
ous carrier prior to administration . The pH of the compound of the compound , the health and condition of the patient , and 
preparations typically will be between 3 and 11 , the judgment of the prescribing physician . The proportion or 
preferably from 5 to 9 and most preferably from 7 to 8. It 60 concentration of a compound provided herein in a pharma 
will be understood that use of certain of the foregoing ceutical composition can vary depending upon a number of 
excipients , carriers , or stabilizers will result in the formation factors including dosage , chemical characteristics ( e.g. , 
of pharmaceutical salts . hydrophobicity ) , and the route of administration . For 
The compositions can be formulated in a unit dosage example , the compounds provided herein can be provided in 
form , each dosage containing from about 5 to about 1000 mg 65 an aqueous physiological buffer solution containing about 
( 1 g ) , more usually about 100 to about 500 mg , of the active 0.1 to about 10 % w / v of the compound for parenteral 
ingredient . The term " unit dosage forms ” refers to physically administration . Some typical dose ranges are from about 1 
more 
newor 
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mg / kg to about 1 g / kg of body weight per day . In some Mycobacterium nonchromogenicum / terrae clade include , 
embodiments , the dose range is from about 0.01 mg / kg to for example , M. hiberniae , M. nonchromogenicum , M. ter 
about 100 mg / kg of body weight per day . The dosage is rae , M. triviale , and Mycolactone - producing mycobacteria ; 
likely to depend on such variables as the type and extent of Mycobacterium simiae clade include , for example , M. progression of the disease or disorder , the overall health 5 
status of the particular patient , the relative biological effi triplex , M. genavense , M. florentinum , M. lentiflavum , M. 
cacy of the compound selected , formulation of the excipient , palustre , M. kubicae , M. parascrofulaceum , M. heidelber 
and its route of administration . Effective doses can be gense , M. interjectum , and M. simiae ; 
extrapolated from dose - response curves derived from in Mycobacterium chelonae clade include , for example , M. 
vitro or animal model test systems . 10 abscessus , M. chelonae , and M. bolletii ; 
Methods of Use Mycobacterium fortuitum clade include , for example , M. The compounds provided herein can be used as antibac fortuitum , M. fortuitum , M. boenickei , M. peregrinum , M. terial agents , in particular , antimycobacterial agents . In some porcinum , M. senegalense , M. septicum , M. embodiments , the bacterial infection is a Gram - positive leansense , M. houstonense , M. mucogenicum , M. mager organism that either uptakes mycolic acid , uses mycolic acid 15 
in a biosynthetic process , synthesizes mycolic acid , or itense , M. brisbanense , and M. cosmeticum ; 
requires mycolic acid as a nutritional supplement . For Mycobacterium parafortuitum clade include , for example , 
example , the compounds provided herein can used to treat a M. parafortuitum , M. austroafricanum , M. diernhoferi , M. 
patient infected with a mycobacterium . In some embodi hodleri , M. neoaurum , and M. frederiksbergense ; 
ments , the compounds provided herein can inhibit the 20 Mycobacterium vaccae clade include , for example , M. growth of a mycobacterium ( e.g. , Mycobacterium tubercu aurum and M. vaccae ; losis ) . Accordingly , provided herein is a method for treating 
a mycobacterial infection in a mammal comprising admin CF include , for example , M. chitae and M. fallax . 
istering a therapeutically effective amount of a compound Additional examples of mycobacterium include , for 
provided herein . 25 example , M. branderi , M. cookie , M. celatum , M. bohemi 
Without being bound by any theory , the compounds cum , M. haemophilum , M. malnloense , M. szulgai , M. 
provided herein are thought to function through selective leprae , M. lepraemurium , M. lepromatosis , M. africanum , 
inhibition or activation of biological processes that would M. botniense , M. chimaera , M. conspicuum , M. doricum , M. normally process fatty acids , esters , alcohols . In some farcinogenes , M. heckeshornense , M. intracellulare , M. embodiments , the compounds may function as competitive 30 lacus , M. marinum , M. monacense , M. montefiorense , M. or irreversible inhibitors based upon their inclusion of , for murale , M. nebraskense , M. saskatchewanense , M. scrofu example , a strained four - membered ring moiety . By way of laceum , M. shimoidei , M. tusciae , M. xenopi , M. ulcerans , example , certain mycolic acids are found in the cell wall of M. pseudoshottsii , M. shottsii , M. confluentis , M. flavescens , M. tuberculosis ; in particular , a - mycolic acid , which incor M. madagascariense , M. phlei , M. smegmatis , M. goodii , M. porates two cyclopropane rings . The presence of cyclopro- 35 wolinskyi , M. thermoresistibile , M. gadium , M. komossense , panes are thought to contribute to the structural integrity of M. obuense , M. sphagni , M. agri , M. aichiense , M. alvei , M. the cell wall and protect the vacillus from oxidative stress 
inside macrophages . Mycolic acids are assembled in myco arupense , M. brumae , M. canariasense , M. chubuense , M. conceptionense , M. duvalii , M. elephantis , M. gilvum , M. bacteria from shorter - chain fatty acid feedstocks . The com hassiacum , M. holsaticum , M. immunogenum , M. massil pounds provided herein can be taken up into the bacteria my 40 iense , M. moriokaense , M. psychrotolerans , M. pyreniv mimicking these feed stocks and can , for example , disrupt orans , M. vanbaalenii , M. pulveris , M. arosiense , M. auba mycolic acid biosynthesis through the presence of their gnense , caprae , M. chlorophenolicum M. strained four - membered ring moieties . fluoroanthenivorans , M. kumamotonense , M. novocastrense , Mycobacterium include , for example , bacteria which are 
members of the groups including Mycobacterium tubercu- 45 seoulense , M. tokaiense , and M. intermedium . M. parmense , M. phocaicum , M. poriferae , M. rhodesiae , M. losis complex ( MTBC ) , Mycobacterium avium complex 
( MAC ) , Mycobacterium gordonae clade , Mycobacterium In some embodiments , the mycobacterium is a member of 
kansasii clade , Mycobacterium nonchromogenicum / terrae MTBC . For example , M. tuberculosis , the major cause of 
clade , Mycolactone - producing mycobacteria , Mycobacte human tuberculosis , M. bovis , M. bovis BCG , M. avium . In 
rium simiae clade , Mycobacterium chelonae clade , Myco- 50 some embodiments , the mycobacterium is M. tuberculosis . 
bacterium fortuitum clade , Mycobacterium fortuitum clade , In some embodiments , the mycobacterium is M. bovis . In 
Mycobacterium parafortuitum clade , Mycobacterium vac some embodiments , the mycobacterium is M. avium sub 
cae clade , and CF. species paratuberculosis . 
For example , each of the groups include the following In some embodiments , one or more compounds provided 
bacteria as members : 55 herein are administered with another antibiotic useful for 
Mycobacterium tuberculosis complex ( MTBC ) include , treating mycobacterial infections . These additional antibiot 
for example , M. tuberculosis , M. bovis , M. bovis BCG , M. ics may include : ethambutol , isoniazid , pyrazinamide , mem 
africanum , M. canetti , M. caprae , M. microti , and M. bers of the rifamycin class ( including , for example , rifam 
pinnipedii ; picin ) , aminoglycosides ( for example , amikacin or 
Mycobacterium avium complex ( MAC ) include , for 60 kanamycin ) , polypeptides ( for example , capreomycin , vio 
example , M. avium , M. avium paratuberculosis , M. avium mycin , or enviomycin ) , fluoroquinolones ( for example cip 
silvaticum , M. avium “ hominissuis ” , M. colombiense , and rofloxacin levofloxacin , or moxifloxacin ) , ethionamide , pro 
M. indicus pranii , thionamide , cycloserine , any other antibiotic employed as 
Mycobacterium gordonae clade include , for example , M. part of a therapeutic treatment for mycocaterial infections , 
asiaticumm and M. gordonae ; 65 and any combination of the antibiotics listed above . The 
Mycobacterium kansasii clade include , for example , M. additional antibiotic can be administered before , after , or 
gastri and M. kansasii ; simultaneously with a compound as provided herein . 
M. 
20 
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Amphiphilic Polymers 
Certain of the compounds provided herein are can be used 
as monomers to produce amphiphilic polymers . Such reac 
tions can prepare a variety of polymers such as those shown 
in Scheme 1 . 
Scheme 1 
Ph 




Grubbs ' I and II 
OMe 
COOMe 
Compounds of Formula ( IV ) can be used to prepare 
polymers using any number of known polymerization reac 




R4 R3 — Z 




R3 is absent or is an optionally substituted C1 - C40 alkyl ; 
R4 is H or an optionally substituted C - C40 alkyl ; and 
Z is selected from the group consisting of : CORF , COZR “ , 
NHC ( O ) NR ° RY , CONR , OCOR , OR ° , SR6 , NR R7 , 
and OPOZR " ; 
Ris H or C.-C. alkyl ; 
R and R7 are independently H or C - C6 alkyl ; 
wherein the hydrocarbon backbone formed by R * and R3 - Z 
is amphiphilic . 
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In some embodiments , at least one of R3 or R * is a C , -C40 thioester , a thioacetate , or a thioformate ) , an alkoxyl , a 
alkyl . For example , if R * is H , then R ’ is a C. - C40 alkyl ( e.g. , phosphoryl , a phosphate , a phosphonate , a phosphinate , an 
C5 - C20 alkyl , C1 - C3 , alkyl , and CZ - C , alkyl ) , or if R * is amino , an amido , an amidine , an imine , a cyano , a nitro , an 
absent , then R * is C , -C40 alkyl ( e.g. , C3 - C20 alkyl , C10C30 azido , a sulfhydryl , an alkylthio , a sulfate , a sulfonate , a 
alkyl , and C2 - C , alkyl ) . In some embodiments , R3 is a 5 sulfamoyl , a sulfonamido , a sulfonyl , a carbocyclyl , a het 
C1 - C10 alkyl . In some embodiments , R? is a C , -C10 alkyl . erocyclyl , an aralkyl , a heteroaralkyl , or an aromatic or 
For example , Rº can be a C , alkyl . In some embodiments , R4 heteroaromatic moiety . 
is a C , -C10 alkyl . For example , R4 can be a Cg alkyl . In some In some embodiments , the hydrocarbon backbone formed 
embodiments , R4 is H. R3 and R + can be independently by R3 and R * is a fatty acid or a derivative thereof which 
optionally substituted . For example , substituents include , 10 contains a cyclobutene moiety . In some embodiments , R3 
but are not limited to , Cy ' , C1-6 alkyl , C2-6 alkenyl , C2-6 and R * together with the cyclobutene moiety form a hydro 
alkynyl , halo , C1-6 haloalkyl , CN , NO2 , ORI , SRAI , C ( O ) carbon chain with a reactive group at one terminus ( e.g. , 
Rbi , C ( O ) NRCIRIT , C ( O ) Oral , OC ( O ) Rb1 , OC ( O ) NRCIRI , carboxylic acid or a Z moiety as defined above ) . In some 
CÁNR ) NRCRá , NRCICENR NRCIRI NR IRAI , embodiments , the hydrocarbon chain ranges from 10 to 30 
NRC (O ) R51 , NRCC ( O ) ORI , NRCIC ( O ) NRCIRPI , NRCS 15 carbon atoms and may be substituted or unsubstituted . 
( O ) RÓI , NRCIS ( O ) Rb1 , NRC'S ( O ) NRC?R I , S ( O ) R51 , S ( O ) Non - limiting examples include myristoleic acid , pamitoleic 
NRCIRd1 , S ( O ) , Rb1 and S ( O ) 2NRIRdI ; acid , sapienic acid , oleic acid , linoleic acid , linolenic acid , 
each Cyl is independently C6-10 aryl , C3-10 carbocyclyl , arachadonic acid , elaidic acid , and vaccenic acid . 
5-10 membered heteroaryl or 4-10 membered heterocyclyl , In some embodiments , Z is CO2R “ . 
each of which is unsubstituted or substituted by 1 , 2 , 3 , 4 or 20 As noted above , any known method of polymerization for 
5 substituents independently selected from C1-6 alkyl , C , alkenes may be used with the monomers described herein . 
alkenyl , C2-6 alkynyl , halo , CN , NO2 , ORCI , SRal , C ( O ) RI , For example , in the presence of selected transition metal 
C ( O ) NRCRdi , C ( O ) ORT , OC ( O ) RbI , OC ( O ) NRCIRDI catalysts , a monomer as provided herein can undergo 
CENREINRIR NRCCSNRI )NRCIRI NRCIRI , metathesis with other alkenes . In the absence of a thermo 
NRC COROT , NR C ( O ) ORI , NRIC ( O ) NRCIRI ,NR IS 25 dynamic driving force , these exchange reactions typically 
( O ) R51 , NRCIS ( O ) , Rb1 , NRCIS ( O ) NRC?R ( I , S ( O ) R51 , S ( 0 ) produce mixtures of the starting and product alkenes . For the 
NRCIR'l , s ( o ) R67 ; s ( 0 ) 2NR Rd and oxo ; monomers provided herein , however , the metathesis reac 
each Ral , Rbi , Rei , Rd1 , is independently selected from H , tion is driven forward by relief of strain to result in rapid and 
C1-6 alkyl , C1-4 haloalkyl , C2-6 alkenyl , C2-6 alkynyl , C6-10 typically irreversible ring - opening metathesis polymeriza 
aryl , C3-10 carbocyclyl , 5-10 membered heteroaryl , 4-10 30 tion ( ROMP ) . As shown in Scheme 2 for a ROMP process 







cyclyl - C1-4 alkyl , ( 5-10 membered heteroaryl ) -C1-4 alkyl or See , for example , Bielawski , Christopher W .; and Grubbs , 
( 4-10 membered heterocyclyl ) -C1-4 alkyl , wherein said C1-6 Robert H. , Progress in Polymer Science ( 2007 ) , 32 ( 1 ) , 1-29 . 
alkyl , C2-6 alkenyl , C2-6 alkynyl , C6-10 aryl , C3-10 carbocy- 45 Publisher : Elsevier Ltd .; Trimmel , Gregor , et al . Advances in 
clyl , 5-10 membered heteroaryl , 4-10 membered heterocy Polymer Science ( 2005 ) , 176 ( Metathesis Polymerization ) , 
clyl , C6-10 aryl - C1-4 alkyl , C3-10 carbocyclyl - C1-4 alkyl , 43-87 . Publisher : Springer GmbH ; Slugovc , Christian , Mac 
( 5-10 membered heteroaryl ) -C1-4 alkyl and ( 4-10 membered romolecular Rapid Communications ( 2004 ) , 25 ( 14 ) , 1283 
heterocyclyl ) -C 1.4 alkyl is optionally substituted with 1 , 2 , 3 , 1297 ; Grubbs , Robert H. and Khosravi , Ezat . Materials 
4 , or 5 substituents independently selected from C4-4 alkyl , 50 Science and Technology ( 1999 ) , 20 ( Synthesis of Polymers ) , 
C14 haloalkyl , halo , CN , OR04 , SR44 , C ( O ) Rb4 , C ( O ) 65-104 Publisher : Wiley - VCH ; Buchmeiser , Michael R. NR 4R04 , C ( O ) ORC4 , OC ( O ) R54 , OC ( O ) NR * R44 , NR 4R04 , Chemical Reviews ( Washington , D.C. ) ( 2000 ) , 100 ( 4 ) , NRC4C ( O ) Rb4 , NRC4C ( O ) NRC4R04 , NR 4C ( O ) ORC4 1565-1604 ; Madan , Rajni , et al . , Progress in Polymer Sci CNR 4 ) NRC4R14 , NROCENR4 )NR 4R44 , S ( O ) Rb4 , ence ( 1998 ) , 23 ( 4 ) , 621-663 . 
S ( O ) NRC4R04 , S ( O ) 2Rb4 , NRCAS ( O ) 2Rb4 , NRC + S ( 0 ) 2 55 With a monomer as provided herein , an example reaction 
NR 4Rd4 and S ( O ) 2NRC4Rd4 ; is as shown in Scheme 3 . 
each Ra4 , R64 , RC4 and Rd4 is independently selected from 
H , C1-4 alkyl , C1-4 haloalkyl , C2-4 alkenyl and C2-4 alkynyl , 
wherein said C1-4 alkyl , C2-4 alkenyl , and C2-4 alkynyl , is 
optionally substituted with 1 , 2 , or 3 substituents indepen- 60 
dently selected from OH , CN , amino , halo , C -4 alkyl , C1-4 
alkoxy , C1-4 alkylthio , C1-4 alkylamino , di ( C1-4 alkyl ) amino , 
C -4 haloalkyl , and C.4 haloalkoxy . Grubbs ' 
In some embodiments , the substituents can be selected 
from the group consisting of an alkyl , a halogen , a hydroxyl , 65 C3H17 THF , ethylvinyl ether 
an alkoxyl , a carbonyl ( such as a carboxyl , an alkoxycar 






???? Ph Fh_1 ( 1 mol % ) OH 
61 % 









ci | Grubbs ' 
???? Ph 1st ( 5 mol % ) 
CH2Cl2 , ethylvinyl ether 
C8H17 5 





In some embodiments , one or more monomers as pro 
vided herein can be reacted with other alkenes , either 
monomeric alkenes or alkene - containing polymers , through 
cross metathesis ( CM ) wherein two alkenes can undergo 
transalkylidenation under release of ethane in the presence 
of a ruthenium carbenoid ( e.g. , Grubbs ' Catalyst ) . In the 
absence of a thermodynamic driving force , these exchange COOH 68 % 
reactions typically produce mixtures of the starting and C8H17 product alkenes . For the cyclobutene - containing monomers 
provided herein , however , the cross metathesis reaction is 
driven forward by relief of strain . Two exemplary reactions 20 For example , a polymer can be prepared as follows . 
with monomeric alkenes are shown in Scheme 4 . Under an inert atmosphere , a solution of catalyst ( Grubbs ' I 
or II ) in THF was added to a vigorously stirred solution of 
0.2 M monomer in THF . The reaction mixture is then stirred 
Scheme 4 for about 30 min at room temperature after which the 
reaction is terminated by addition of a small amount of ethyl 
vinyl ether . The mixture is allowed to stir at room tempera 
C2H17 ture for 30 min . and poured into methanol to precipitate the 
polymer . The polymer is then resolubilized in dry THF and 
the solutions dried with typical agents ( magnesium sulfate , 
c | Grubbs ' sodium sulfate ) before further purification reprecipitation 
???? Ph 1st ( 5 mol % ) using dry methanol ( 2x ) . The polymer can be analyzed by 
CH2Cl2 gel permeation chromatography ( GPC ) in THF or by proton 
35 ' H NMR as a solution in CDC1z . 
In some embodiments , radical polymerization methods 
may be used to prepare a polymer as provided herein . Free 
radical polymerization is a method of polymerization by 
which a polymer forms by the successive addition of free 73 % 40 COOH 
radical building blocks . Free radicals can be formed via a 
number of different mechanisms usually involving separate 
initiator molecules . Following its generation , the initiating 
free radical adds ( nonradical ) monomer units , thereby grow 
ing the polymer chain . Any reasonable initiator may be used 
C2H17 in these polymerization reactions . An example of such a 
reaction is shown in Scheme 5 . 
OH + 
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The cyclobutene compounds provided herein are also In some embodiments , the diene can be a substituted 
useful in bioorthogonal " click " chemistries . Bioorthogonal tetrazine or other heteroaromatic ring system with at least 
reactions for coupling materials in the presence of complex two nitrogens adjacent to each other and which is a highly 
biological milieu are of great interest in biology and medi reactive participant in the inverse electron demand Diels 
cine . Such reactions have become key components in a 5 Alder reaction . The diene is linked to the payload ( which can 
variety of applications including protein engineering , immu be , e.g. , a therapeutic agent , fluorescence dye , or other 
noassay development , and cell surface modification . ( Link J detectable agent ) . In these embodiments , the diene possesses A et al . , 2003 , Curr Opin Biotechnol 14 : 603-609 ; Wang a reactive group such as an amine , alcohol , carboxylic acid et al . , 2003 , J Am Chem Soc 12 : 3192-3193 ; Dimandis E P et 
al . , 1991 , Clin Chem 37 : 625-636 ; Baskin J M et al . , 2007 , 10 with the reactive moiety on the payload to form a link or ester , or other group that can undergo a chemical reaction Proc Natl Acad Sc . USA 104 : 16793-16797 ; Link J A et al . , between the two . 2003 , J Am Chem Soc 125 : 11164-11165 ) . Presently , a few 
types of bioorthogonal reactions have been reported , the Dienes 
most popular being the Staudinger ligation and the [ 3 + 2 ] Dienes useful in the present disclosure include but are not 
cycloaddition “ click ” reaction between azides and alkynes . 15 limited to aromatic ring systems that contain two adjacent 
( Prescher J A et al . , 2004 , Nature 430 ( 7002 ) : 873-877 ; nitrogen atoms , for example , tetrazines , pyridazines , substi Rostovtsev V V et al . , 2002 , Angew Chem Int Ed 41 ( 14 ) : tuted or unsubstituted 1,2 - diazines . Other 1,2 - diazines can 2596-2599 ) . include 1,2 - diazines annelated to a second n - electron - defi Bioorthogonal “ click ” chemistries are widely used in cient aromatic ring such as pyrido [ 3,4 - d ] pyridazines , chemical biology for a myriad of applications such as 20 pyridazino [ 4,5 - d ] pyridazines , and activity based protein profiling , crosslinking of proteins , 1,2,4 - triazines . 
monitoring cell proliferation , generation of novel enzyme Pyridazines can also be fused with a five - membered hetero 
inhibitors , monitoring the synthesis of newly formed pro cycle such as imidazo [ 4,5 - d ] pyridazines and 1,2,3 - triazolo 
teins , protein target identification , and studying glycan pro [ 4,5 - d ] pyridazines . In some preferred embodiments , the 
cessing . Perhaps the most fascinating applications involve 25 diene is an asymmetrical tetrazine as described herein , e.g. , 
using these bioorthogonal chemistries to assemble mol 3- ( p - Benzylamino ) -1,2,4,5 - tetrazine : 
ecules in the presence of living systems such as live cells or 
even whole organisms ( Baskin et al . , 2007 , Proc Natl Acad 
Sci USA , 104 , 16793-7 ; Laughlin et al . , 2008 , Science , 320 , H2N 
664-7 ; Prescher and Bertozzi , 2005 , Nat Chem Biol , 1 , 
13-21 ; Neef and Schultz , 2009 , Angew Chem Int Ed Engl , 
48 , 1498-500 ; Ning et al . , 2008 , Angewandte Chemie 
International Edition , 47 , 2253-2255 ) . These latter applica 
tions require that the chemistry be non - toxic and possess 
kinetics that allow fast reaction to occur with micromolar 35 
concentrations of reagents in a time span of minutes to 
hours . 
Bioconjugation methods using inverse electron demand 
Diels - Alder cycloadditions between tetrazines and highly 
strained dienophiles such as norbomene and trans - cy- 40 
clooctene are known in the literature , however the tetrazine 
used has limited stability to aqueous media . ( Blackman et Two non - limiting examples of such a “ click ” chemistry 
al . , 2008 , J Am Chem Soc , 130 , 13518-9 ; Devaraj et al . , reaction is show in Scheme 6 . 
2009 , Angew Chem Int Ed Engl , 48 , 7013-6 ; Devaraj et al . , 
2008 , Bioconjug Chem , 19 , 2297-9 ; Pipkom et al . , 2009 , J 45 
Pept Sci , 15 , 235-41 ) . To improve upon the stability of the Scheme 6 
tetrazine , a novel asymmetric tetrazine was employed that 
NEN demonstrated superior stability in water and serum and can 
react with trans - cyclooctene at rates of approximately 103 
M- sec - 1 at 37 ° C. ( Devaraj et al . , 2009 , Angew Chem Int 50 
Ed Engl , 48 , 7013-6 ) . This extremely fast rate constant 
allows for the labeling of extracellular targets at low nano 3,6 - di ( 2 - pyridyl ) -tetrazine 
molar concentrations of tetrazine labeling agent , concentra 
tions that are sufficiently low to allow for real - time imaging 
of probe accummulation . 
In some embodiments , the ligand , e.g. , an antibody , small 
molecule or other biomolecule , can be physically attached to C3H17 
the dienophile . In some embodiments , the ligand carries a N 
functional group such as an amine , alcohol , carboxylic acid 
or ester , or other group of atoms on the ligand that can 60 
undergo a chemical reaction allowing attachment to the 
dienophile . Alternatively or in addition , the dienophile or 
heterodienophile ( e.g. , a cyclobutene compound as provided About 75 % conversion herein ) possesses a reactive functional group for attachment With 53 % yield 
to the ligand ( e.g. , Z ) . Thus , the reactive functional group on 65 
the ligand and / or dienophile undergoes a chemical reaction 










1 hr . 30 min . 
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carbon double bonds which provide the cross - linking ele 
ment can be cross - linked by the same methods used for latex 
of butadiene rubbers , allowing the incorporation of a two 
dimensional crosslink within a coating or layer . 
The polymers provided herein can form two - dimensional 
COOH or three - dimensional ordered polymers or coatings . For 




c 10 Scheme 7 N 
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Accordingly , provided herein is an amphiphilic polymer 25 
formed by polymerizing a compound as provided herein 
( e.g. , a compound of Formula ( IV ) or an amphiphilic 
cycloalkene - containing fatty acid derivative ) , each having a 
hydrophobic end , a hydrophilic end , and a backbone there 
between comprising a cycloalkene , wherein the cycloalkene 30 
comprises at least four carbon atoms , with at least two of the 
four carbon atoms being part of the backbone of the amphi 
philic cycloalkene - containing fatty acid derivatives . In some 
embodiments , the polymer comprises amphiphilic fatty acid 
derivatives cross - linked via an unsaturated hydrocarbon 35 
chain formed by cleavage of the cycloalkene . In some 
embodiments , the polymer is ordered in two or three dimen 
sions . 
Further provided herein is a polymer comprising a repeat 
ing unit having the structure 
== C - CR ! _CR - C = ) = , 
where : 
Rl is hydrophobic and comprises a substituted or unsubsti 
tuted alkyl group having at least one carbon atom or a 45 
substituted or unsubstituted alkenyl group having at least 
two carbon atoms , and 
R² is hydrophilic and comprises a substituted alkyl group 
having at least one carbon atom or a substituted alkenyl 
group having at least two carbon atoms . 
In some embodiments , the substituted alkyl group or 
substituted alkenyl group of R2 comprises a hydroxyl group , 
an ester group , an aldehyde group , a carboxyl group , a 
sulfhydryl group , an amine group , an amide group , a carb 
amide group , or a phosphate group . 
The polymers provided herein may be used in a number 
of applications . For example , the polymers may undergo 
further manipulation such as cleavage , stabilization , and / or 
cross - linking . For example , the carbon - carbon double bonds 
introduced through certain polymerization reactions ( e.g. , 60 
ROMP polymerization ) can be cleaved by oxone or a similar 
oxidant , thus providing a means of breaking the polymer 
back to monomeric components . In some cases , the carbon 
carbon double bonds which provide the cross - linking ele 
ment can be saturated ( hydrogenated ) to form highly stable 65 
alkane linkages , making the polymer much less susceptible 
to oxidative cleavage . In some embodiments , the carbon 
50 
55 
Examples of applications of such polymers or coatings 
include : 
1 ) Polymerization of monolayer or multilayer films 
derived from Langmuir - Blodgett techniques ( either 
directly on a Langmuir trough or after transfer of a 
monolayer or multi layers to a substrate by dipping ) . 
2 ) Polymerization of monolayer or multilayer films 
derived from polar interactions between the amphiphile 
and inorganic or organometallic colloids such as quan 
tum dots . 
3 ) Polymerization within micelles , bilayers , liquid crys 
tals , and liposomes . These aggregates may be com 
posed solely of the amphiphilic cyclobutenes or else 
mixtures of the amphiphilic cyclobutenes with other 
amphiphilic components . 
4 ) Polymerization of monolayer or multilayer films of the 
amphiphilic cyclobutenes onto a chromatographic sup 
port such as silica to create a remarkably stable reverse 
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desired functional group that can be incorporated into The reactions for preparing the compounds provided 
the cyclobutene precursors . By way of comparison , herein can be carried out in suitable solvents which can be 
commercial reverse phase chromatography columns readily selected by one of skill in the art of organic synthesis . are prepared by chemical bonding of C8 or C18 alkyl 
silanes to a silica surface via siloxane bonds . The Suitable solvents can be substantially non - reactive with the 
resulting siloxanes are only stable within a fairly mod starting materials ( reactants ) , the intermediates , or products 
est pH range . If a reverse - phase chromatography col at the temperatures at which the reactions are carried out , 
umn was instead prepared using a cyclobutene - substi e.g. , temperatures which can range from the solvent's freez tuted monomer ( for example , with a terminal siloxane ing temperature to the solvent's boiling temperature . A given grafted onto or in place of the carboxylic acid ) , treat 
ment with a ROMP catalyst could provide a new 10 reaction can be carried out in one solvent or a mixture of 
chromatographic support maintaining the same funda more than one solvent . Depending on the particular reaction 
mental features of existing supports yet possessing far step , suitable solvents for a particular reaction step can be 
greater hydrolytic stability . selected by the skilled artisan . 5 ) The ability to prepare cyclobutenes having a close Preparation of the compounds provided herein can structural analogy to natural fatty acids , combined with 
the facility of achieving cross - metathesis of the involve the protection and deprotection of various chemical 
cyclobutenes with other alkenes , will enable the use of groups . The need for protection and deprotection , and the 
the cyclobutene fatty acid as a means of stabilizing or selection of appropriate protecting groups , can be readily 
solubilizing proteins or chemical reagents within bio determined by one skilled in the art . The chemistry of 
logical membranes . A targeted protein or agent would protecting groups can be found , for example , in Protecting 
be functionalized with one or more alkene units in the Group Chemistry , 1st Ed . , Oxford University Press , 2000 ; 
form of allyl ethers , allyl esters , or allyl amides ) and March's Advanced Organic Chemistry : Reactions , Mecha 
then subjected with cross - metathesis with nisms , and Structure , 5th Ed . , Wiley - Interscience Publica 
cyclobutene fatty acid to create a protein “ decorated ” 25 tion , 2001 ; and Peturssion , S. et al . , " Protecting Groups in 
with fatty acids , fatty acid esters , phospholipids , or Carbohydrate Chemistry , " J Chem . Educ . , 74 ( 11 ) , 1297 
triglycerides . ( 1997 ) . 
6 ) Polymerization or cross - metathesis of cyclobutene Reactions can be monitored according to any suitable 
containing fatty acids , or their conjugates with proteins , method known in the art . For example , product formation 
after absorption within the skin , hair , or nail , would can be monitored by spectroscopic means , such as nuclear 
result in a new class of remarkably durable cosmetic magnetic resonance spectroscopy ( e.g. , ' H or 13C ) , infrared and therapeutic agents . The ability to polymerize the spectroscopy , spectrophotometry ( e.g. , UV - visible ) , mass 
absorbed fatty acid under conditions that selectively spectrometry , or by chromatographic methods such as high 
target the cyclobutene would create strong and biomi performance liquid chromatography ( HPLC ) , liquid chro metic coatings , with potential applications for cosmet- 35 matography - mass spectroscopy ( LCMS ) , or thin layer chro 
ics , skin protective or tanning agents , hair thickeners , matography ( TLC ) . Compounds can be purified by those 
and wound coatings . skilled in the art by a variety of methods , including high 
performance liquid chromatography ( HPLC ) ( “ Preparative Synthesis LC - MS Purification : Improved Compound Specific Method 
Optimization ” K. F. Blom , et al ., J. Combi . Chem . 6 ( 6 ) , 874 
The compounds provided herein , including salts thereof , ( 2004 ) and normal phase silica chromatography . 
can be prepared using known organic synthesis techniques In some embodiments , the compounds provided herein 
and can be synthesized according to any of numerous can be prepared as described in the Examples provided 
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a ) DMAP , DCC , BOH , 85 % ( OA1 ) , 99 % ( DAI ) ; b1 ) Zn dust ( 5 equiv ) , Cl3CCOCI 
( 2.5 equiv ) rt , ether , 85 % for OA2 and 80 % for DA2 ; b2 ) Zn ( Cu ) ( 5 equiv ) , C13CCOCI ( 2.5 
equiv ) , rt , ether 63 % ; c ) NaBH4 , 2 - propanol , 55 % ( OA3 ) , 57 % ( DA3 ) ; d ) MsC1 , Et3N , 92 % ( OA4 and 
DA4 ) ; e ) Na / NH3 , -78 to -33 ° C. , 87 % ( 1 ) , 52 % ( 8 ) ; f ) H2 , Pd / C ETOAc , 96 % ( 2 ) , 89 % ( 9 ) , 87 % ( 3 ) , 90 % 
( 10 ) , 81 % ( 4 ) , 54 % ( 11 ) , 70 % ( 5 ) ; g ) Zn ( 5 equiv ) , ACOH 87 % ( OA5 ) and 59 % ( DA1 ) ; h ) NaBH4 , MeOH , 
-10 ° C. , 99 % for OA6 and 76 % for DA6 ; i ) Zn , ( 1.1 equiv ) , AcOH , 97 % for OA5 and 70 % for EA5 . 
As shown above , the preparation of cyclobutene com tanol ( e.g. , 4 ) analogs can be prepared through a variation of 
pounds as provided herein ( e.g. , 1 ) can occur using the the above in which the initial dichlorocyclobutanone is 
following procedures . The benzyl ester of oleic acid under dehalogenated , for example , with excess zinc in acetic acid . 
goes cycloaddition with dichloroketene to afford a mixture 30 A mixture of regioisomeric monochlorocyclobutanones 
of regioisomeric dichlorocyclobutanones , each predomi ( e.g. , 5 ) can be prepared by partial reduction of the dichlo 
nantly as the cis stereoisomer . The dichlorocyclobutanones rocyclobutanone with 1.1 equiv of Zn or Zn ( Cu ) in acetic acid . For the preparation of cyclobutanone , cyclobutanol and possessed limited stability and are directly reduced with monochlorocyclobutanones , the final step can include sodium borohydride to furnish a mixture of regioisomeric removal of the benzyl ester by Pd - mediated hydrogenolysis . 2,2 - dichloro - 1 - cyclobutanols . Conversion to the corre- 35 Compound having shorter chains ( e.g. , 8-11 ) can be 
sponding methanesulfonate ( mesylate ) esters is followed by prepared analogously from 9 - decenoic acid , furnishing com 
reaction with sodium in ammonia , resulting in simultaneous parably functionalized substrates with lower log P. The 
deprotection of the benzyl ester and fragmentation / reduction trans - stereoisomers of cyclobutenes ( e.g. , 2 ) and monochlo 
of the B - chloromethanesulfonate , generating cyclobutene 1 rocyclobutanones ( e.g. , 7 ) can be prepared using a similar 
in quantities of up to several hundred milligrams . Hydroge- 40 route based upon elaidic acid ( Scheme 9 ) . In some cases , the 
nation of the compound can provide the corresponding cycloaddition step can be conducted only in the presence of 
cyclobutane ( e.g. , 2 ) . A cyclobutanone ( e.g. , 3 ) and cyclobu activated Zn or Zn / Cu . 
Scheme 9 
? . b2 
OH OBn 
EA Elaidic acid 
( EA ) 
HO CI MsO CI 
C 
?? 




EA2 mo C f 
OH OBn 
EA5 7 
a ) DMAP , DCC , BOH , 95 % ( EA1 ) ; b2 ) Zn ( Cu ) ( 5 equiv ) , Cl3CCOCI ( 2.5 equiv ) , it , 
ether 63 % ; c ) NaBH4 , 2 - propanol , 85 % ( EA3 ) ; d ) MsC1 , Et3N , 86 % ( EA4 ) ; e ) Na / NH3 , 
-78 to -33 ° C. , 46 % ( 6 ) ; f ) H2 , Pd / C ETOAc , 54 % ( 7 ) . 
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Accordingly , provided herein is a method comprising : matography was performed on 32-60 um silica gel . Prepara 
reacting an unsaturated fatty acid or derivative thereof tive HPLC was performed on a 21x250 mm normal phase Si 
having a backbone comprising at least one carbon - carbon ( 8 micron ) column at 10 mL / min of the indicated solvent 
double bond with dihaloketene ( e.g. , dichloroketene or unless otherwise noted . Analytical purity of compounds was 
dibromoketene ) to achieve a stereospecific cycloaddition 5 checked using an analytical column ( 250 mmx4.6 mm ; 
across the at least one carbon - carbon double bond , Microsorb ) at 1 mL / min of 20 % EtOAc / Hexane ; detection 
thereby yielding a cycloketone - containing fatty acid was accomplished using a differential refractometer inter 
derivative comprising a cycloketone along the backbone , faced with a data module . All compounds tested for bio 
wherein the cycloketone comprises at least four carbon logical activity showed > 97 % purity by HPLC analysis 
atoms , with at least two of the at least four carbon atoms 10 except for 5 and 7. Melting points are uncorrected . Mass 
being part of the backbone of the cycloketone - containing spectral analyses were carried out by HRFAB on 3 - nitroben 
fatty acid derivative ; zyl alcohol ( 3 - NBA ) or glycerol matrices at the Nebraska 
reducing the cycloketone - containing fatty acid derivative to Center for Mass Spectrometry . 
yield an amphiphilic cycloalkene - containing fatty acid 
derivative having a hydrophobic end , a hydrophilic end , 15 Example 1 Preparation of Compounds 
and a backbone therebetween comprising a cycloalkene , 
wherein the cycloalkene comprises at least four carbon ( Z ) -9 - Octadecenoate , benzyl ester ( benzyl oleate , OA1 ) 
atoms , with at least two of the four carbon atoms being was prepared by a variation of a known procedure ( Ravigli 
part of the backbone of the amphiphilic cycloalkene one , M. et al . Lancet 2012 , 379 : 1902-1913 ) . Benzyl alcohol 
containing fatty acid derivative . 20 ( 3.83 g , 35.4 mmol ) was added to a stirred solution of oleic 
In some embodiments , the method further comprises acid ( 5.136 g , 18.1 mmol ) and DMAP ( 43.7 mg , 3.57 mmol ) 
polymerizing a multiplicity of the amphiphilic cycloalkene in CH C12 ( 40 mL ) . The solution was cooled to 0 ° C. and 
containing fatty acid derivatives to yield a polymer com DCC ( 4.211 g , 20.4 mmol ) was added . The mixture was 
prising carbon - carbon double bonds . In some such embodi allowed to warm to room temperature and was stirred for 2.5 
ments , polymerization can include cross - linking the 25 hours . The resulting suspension was filtered through a cotton 
amphiphilic cycloalkene - containing fatty acid derivatives plug and the precipitate was washed with CH C12 . The 
via the carbon - carbon double bond in the cycloalkene . In CH , C1 , solution was washed with water and dried over 
some embodiments , polymerizing the multiplicity of the Na2SO4 . Evaporation of the organic solvent and flash chro 
amphiphilic cycloalkene - containing fatty acid derivatives matography of the residue over silica gel , using 5 % EtOAc / 
comprises ring - opening metathesis reactions . In some 30 Hex , gave benzyl oleate OA1 ( 5.73 g , 85 % ) as a colorless 
embodiments , polymerizing the multiplicity of the amphi oil : R = 0.83 ( 10 % EtoAc / Hex ) ; IR ( ZnSe , cm - l ) 2924 , 
philic cycloalkane - containing fatty acid derivatives com 2853 , 1738 , 1456 , 1162 , 696 cm- ?; ' H NMR : 8 7.38-7.31 
prises click - chemistry . For example , the amphiphilic ( 5H ) , 5.41-5.31 ( 2H ) , 5.13 ( s , 2H ) , 2.37 ( t , J = 7.6 Hz , 2H ) , 
cycloalkane - containing fatty acid derivative can be reacted 2.05-2.00 ( 4H ) , 1.70-1.62 ( m , 2H ) , 1.40-1.29 ( 20H ) , 0.90 ( t , 
with a substituted or unsubstituted tetrazine . 35 J = 6.8 Hz , 3H ) ; 13C NMR 8 173.6 , 136.12 , 129.9 , 129.7 , 
In some embodiments , the method further comprises 128.5 ( two overlapping signals ) , 128.11 , 128.09 , 66.0 , 34.3 , 
hydrogenating the carbon - carbon double bonds of the poly 31.9 , 29.7 , 29.6 , 29.50 , 29.3 , 29.1 , 29.1 , 27.2 , 27.1 , 24.9 , 
mer . In some embodiments , the method further comprises 22.7 , 14.1 . 
cleaving at least some of the carbon - carbon double bonds in 2,2 - Dichloro - 4 - octanoic acid benzyl ester , 8 - yl ) 3 - octyl 
the polymer via oxidation to yield monomeric products . 40 cyclobutanone- ; 2,2 - Dichloro - 3- ( octanoic acid benzyl ester , 
The backbones of the multiplicity of the amphiphilic 8 - yl ) 4 - octylcyclobutanone ( OA2 ) ; was prepared by a modi 
cycloalkene - containing fatty acid derivatives can be aligned fication of a known procedure ( Raviglione , M. et al . Lancet 
before polymerizing the multiplicity of the amphiphilic 2012 , 379 : 1902-1913 ) . To a mixture of zinc dust ( 0.879 g , 
cycloalkene - containing fatty acid derivatives . 13.4 mmol ) and benzyl oleate OA1 ( 1.019 g , 2.73 mmol ) in 
45 20 mL of anhydrous ether was slowly added a solution of 
EXAMPLES trichloroacetyl chloride ( 0.75 mL , 6.8 mmol ) in 7 mL of 
diethyl ether via dropping funnel over a period of 45 min . 
The invention is further described in the following The reaction was stirred until judged complete by the 
examples , which do not limit the scope of the invention absence of starting material ( 4 h , TLC ) . The reaction mixture 
described in the claims . 50 was filtered through a plug of Celite and the residue was 
General Procedures washed with ether ( 2x75 mL ) . The organic solution was 
All reagents and solvents were used as purchased except stirred a minimum with 50 % aq . NaHCO3 and the separated 
for pyridine and CH C12 ( distilled from CaH , and kept under aqueous layer back - extracted with ether ( 2x20 mL ) . The 
N2 ) and THF ( distilled from Na / benzophenone under N2 ) . combined organic layers were dried over Na2SO4 and con 
Thin - layer chromatography ( TLC ) was performed on 0.25 55 centrated under vacuum to give 1.3041 g of the product 
mm hard - layer silica G plates ; developed plates were visu ( 99 % ) as a yellow oil . The unpurified material was generally 
alized with a hand - held UV lamp or by staining : 1 % used directly for the next reaction because of a tendency to 
Ce ( SO4 ) 2 and 10 % ( NH4 ) 2M004 in 10 % aq . H2SO4 ( general decompose during chromatography . However , small quan 
stain , after heating ) ; 1 % aq . KMnO4 ( for unsaturated com tities could be purified by rapid flash chromatography ( 5 % 
pounds ) ; 3 % vanillin in 3 % H2SO4 in EtOH ( general stain , 60 EtoAc / Hex ) to afford a 1 : 1 mixture of regioisomeric dichlo 
after heating ) . Unless otherwise noted , NMR ( spectra were rocyclobutanones OA2 as a colorless oil : R , 0.53 ( 10 % 
recorded at 400 MHz ( ' H ) or 100 MHz ( 13C ) in CDC13 ; EtOAc / Hex ) ; IR ( ZnSe , cm - 1 ) 2926 , 2855 , 1800 , 1735 , 
peaks are reported as : chemical shift ( multiplicity , J cou 1456 , 1162 , 696 cm - l ; ' H NMR : d 7.36-7.32 ( 5H ) , 5.120 / 
plings in Hz , number of protons ) ; " app ” and “ br ” refer to 5.116 ( overlapping s , 2H ) , 3.55-3.49 ( m , 1H ) 2.97-2.93 ( m , 
apparent and broad signals , respectively . IR spectra were 65 1H ) , 2.37 / 2.35 ( overlapping t , J = 7.6 Hz , 2H ) , 1.74-1.62 ( m , 
recorded as neat films ( ZnSe , ATR mode ) with selected 4H ) , 1.66-1.48 ( m , 4H ) , 1.45-1.27 ( br m , 18H ) , 0.89 / 0.88 
absorbances reported in wavenumbers ( cm- ? ) . Flash chro ( overlapping triplets , J = 6.9 Hz , total 3H ) ; 13C NMR 8 197.5 , 
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173.5 , 136.1 , 128.5 , 128.1 , 88.1 , 66.0 , 58.0 , 57.9 , 49.4 , 49.4 , Second - eluting cis : R = 0.20 ; IR ( ZnSe , cm ' ) 3464 , 2924 , 
34.2 , 31.8 , 31.80 , 29.60 , 29.3 , 29.3 , 29.2 , 29.18 , 29.15 , 2854 , 1736 , 1456 , 1169 , 696 cm- ' ; ' H NMR : 8 7.37-7.32 
29.12 , 29.0 , 28.9 , 28.9 , 28.04 , 27.96 , 26.72 , 26.68 , 26.3 ; ( m , 5H ) , 5.11 ( s , 2H ) , 4.55 ( dd , J = 10.8 , 8.8 Hz , 1HCH - OH , 
HRFAB - MS ( 3 - NBA + Li matrix ) : calcd . for C27H4003C12Li cis to the backbone assigned based on 2D - NOESY analysis 
[ M + Li ] * : 489.2515 . Found : 489.2499 . 5 and 43 diagonal 1-0 ) , 2.72 ( dt , J = 9.2 , 5.6 Hz , 1H ) , 2.65 ( d , 
2,2 - Dichloro - 4- ( octanoic acid benzyl ester , 8 - yl ) 3 - octyl J = 10.8 Hz , 1H , OH ) , 2.54 ( app dq , v = 9.2 , 5.6 Hz , 1H ) , 
cyclobutanol- ; 2,2 - Dichloro - 3- ( octanoic acid benzyl ester , 2.35 ( t , J = 7.2 Hz , 2H ) , 1.68-1.60 ( bm , 3H ) , 1.52-1.13 ( m , 
8 - yl ) 4 - octylcyclobutanol ( OA3 ) . Reduction of the dichlo 24H ) , 0.89 ( app t , J = 6.8 Hz , 3H ) ; 13C NMR 8 173.7 , 136.1 , 
rocylobutanone OA2 was achieved using a known procedure 128.5 ( two overlapping signals ) , 128.2 ( two overlapping 
( Raviglione , M. et al . Lancet 2012 , 379 : 1902-1913 ) . To a 0 ° 10 signals ) , 93.5 , 77.2 , 66.1 , 49.5 , 40.9 , 34.3 , 31.8 , 29.6 , 29.4 , 
C. solution of the mixture of regioisomeric dichlorocyclobu 29.2 , 29.1 , 29.04 , 29.00 , 27.0 , 25.8 , 24.8 , 23.2 , 22.7 , 14.1 ; 
tanones OA2 ( 1.5 g , 3.1 mmol ) in iPrOH ( 45 mL ) was added HRFAB - MS ( 3 - NBA matrix ) : calcd . for C27H4303C12 : 
NaBH4 ( 0.176 g , 4.65 mmol ) . The reaction was allowed to 485.2589 [ M + H ] * . Found : 485.2581 . 
slowly warm to rt and stirred only until the starting material Second - eluting trans : R = 0.15 ; IR ( ZnSe , cm- ) 3464 , 
had disappeared ( TLC , -2.5 h ; byproducts tended to accu- 15 3033 , 2925 , 2854 , 1738 , 1498 , 1160 , 697 cml ;' H NMR : 8 
mulate upon prolonged reaction ) . The reaction was then 7.37-7.32 ( m , 5H ) , 5.11 ( s , 2H ) , 3.99 ( ddd , J = 10.0 , 8.4 , 1.2 
cooled to 0 ° C. and quenched with 1N HCl ( 40 ml ) . The Hz , 1H , CH OH , trans to the backbone assigned based on 
solution was stirred for an additional 30 min and then 2D - NOESY analysis and 41 , ' diagonal H = 1.2 Hz ) , 2.69-2.64 ( m , 
extracted with EtOAC ( 3x100 mL ) . The organic layer was 1H ) , 2.56 ( d , J = 10.0 Hz , 1H , OH ) , 2.35 ( t , J = 7.6 Hz , 2H ) , 
washed sequentially with water / sat . NaHCO3 / brine and then 20 2.26-2.22 ( m , 1H ) , 1.66-1.26 ( m , 27H ) , 0.88 ( app t , J = 6.8 
dried over Na S04 . Evaporation of the organic solvent and Hz , 3H ) ; 13C NMR 8 173.7 , 136.1 , 128.5 ( two overlapping 
flash chromatography of the residue on silica gel , using a signals ) , 128.2 ( two overlapping signals ) , 91.1 , 82.6 , 66.1 , 
step gradient of 5 % / 10 % EtOAc / Hex , gave 0.8212 g ( 55 % 50.3 , 44.3 , 34.3 , 31.8 , 29.7 , 29.4 , 29.2 , 29.04 , 28.97 , 28.5 , 
yield ) of a 1 : 1 mixture of regioisomeric cyclobutanols S2 as 28.21 , 28.18 , 27.5 , 24.8 , 22.7 , 14.1 ; ESI - MS : calcd . for 
a colorless oil . The products were predominantly a regioi- 25 C27H4203C12Na : [ M + Na ] 507.2409 . Found : 507.2426 . 
someric mixture of the cis , cis diastereomers based on ' H 2,2 - Dichloro - 4- ( octanoic acid benzyl ester , 8 - yl ) 3 - octyl 
NMR , HSQC , 2D - COSY and 2D - NOESY analysis : R ( 10 % cyclobutanol , methanesulfonate ester ; 2,2 - Dichloro - 3- ( oc 
EtOAc / Hex ) = 0.33 ( major , OH is cis to backbone ) 0.28 tanoic acid benzyl ester , 8 - yl ) 4 - octylcyclobutanol , meth 
( minor , OH is trans to backbone ) , 0.2 ( major , OH is cis to anesulfonate ester ( OA4 ) was prepared by a variant of 
backbone ) and 0.15 ( minor , OH is trans to backbone ) ; IR 30 published procedures ( see Baldwin , J. D. and Belfield , K. D. 
( ZnSe , cm- ) 3473 , 3036 , 2924 , 2854 , 1733 , 1456 , 1168 , J. Org . Chem . 1987 , 52 , 4772-4776 ; and Powers , D. C. et al . 
696 cm - 7 ; ' H NMR : 8 7.36-7.32 ( m , 5H ) , 5.116 / 5.112 ( app J. Org . Chem . 2007 , 72 , 187-194 ) : Methanesulfonyl chloride 
s , total 2H ) , 4.55 ( dd , J = 10.8 , 8.8 Hz , 0 . CH - OH , cis ( 62 ul , 0.80 mmol ) was slowly added to a stirred 0 ° C. 
to the backbone assigned based on 2D - NOESY analysis and solution of a regioisomeric mixture of cyclobutanols OA3 
4J diagonal 1 +0 ) , 3.99 ( br t , J = 10 Hz , 0.08H ) , 2.75-2.69 ( m , 35 ( 0.193 g , 0.398 mmol ) and triethylamine ( 0.25 mL , 8 mmol ) 
1H ) , 2.64 / 2.62 ( overlapping d , J = 10.8 Hz , total 1H , -H in CH2Cl2 ( 2 mL ) over 15 min . The reaction was allowed to 
proton assigned based on the disappearance of this peak slowly warm to rt and was stirred for 17 h or until no starting 
upon D20 addition ) , 2.60-2.55 ( m , 1H ) , 2.36 / 2.35 ( overlap material remained ( TLC ) . The reaction was diluted with 75 
ping t , J = 7.6 Hz , total 2H ) , 1.67-1.62 ( bm , 3H ) , 1.52-1.19 inL of CH2Cl2 and washed sequentially with 1N HCI ( 2x25 
( 24H ) , 0.89 / 0.88 ( overlapping t , J = 6.8 Hz , total 3H ) . Small 40 mL ) , sat aq . NaHCO3 ( 2x25 mL ) and water ( 2x25 mL ) . The 
quantities of the individual isomers could be isolated by organic solution was then dried with Na2SO4 and concen 
semipreparative HPLC ( 10 % EtOAc / Hex , RI detection ) : trated under reduced pressure . The residue was purified by 
first - eluting cis : R = 0.33 ; IR ( ZnSe , cm- ! ) 3457 , 2924 , flash chromatography using 10 % EtoAc / Hex to give a light 
2854 , 1736 , 1456 , 1170 , 697 cm- ?; ' H NMR : 8 7.37-7.32 yellow oil ( 0.2061 g , 92 % ) consisting of a 1 : 1 mixture of 
( m , 5H ) , 5.12 ( s , 2H ) , 4.55 ( dd , J = 10.8 , 8.8 Hz , 1H , 45 regioisomers , each a 92 : 8 mixture of cis / trans stereoisomers 
CH - OH , cis to the backbone assigned based based upon ' H NMR : R ( 10 % EtOAc / Hex ) = 0.31 ( first 
2D - NOESY analysis and 41 diagonal 1-0 ) , 2.72 ( dt , = 9.2 , 5.6 trans ) , 0.26 ( first cis / second trans ) , 0.21 ( second cis ) ; IR 
Hz , 1H ) , 2.59 ( d , J = 10.8 Hz , 1H , OH ) , 2.55 ( app dq , ( ZnSe , cm- ? ) 3032 , 2925 , 2855 , 1735 , 1458 , 1180 , 696 
J = 9.2 , 5.6 Hz , 1H ) , 2.36 ( t , J = 7.6 Hz , 2H ) , 1.67-1.51 ( br m , cm - 1 ; ' H NMR : 8 7.36-7.33 ( m , 5H ) , 5.33 ( d , J = 9.6 Hz , 
3H ) , 1.52-1.13 ( m , 24H ) , 0.88 ( app t , J = 6.8 Hz , 3H ) ; 13C 50 0.92H ) , 5.114 / 5.109 ( two s , total 2H ) , 4.84 ( d , J = 7.6 Hz , 
NMR 8 173.6 , 136.1 , 128.5 ( two overlapping signals ) , 128.2 0.08H ) , 3.208 / 3.205 ( two s , total 3H ) , 2.76-2.74 ( m , 2H ) , 
( two overlapping signals ) , 93.5 , 77.2 , 66.1 , 49.5 , 40.9 , 34.3 , 2.36 / 2.34 ( two overlapping t , J = 7.6 Hz , total 2H ) , 1.66-1.60 
31.8 , 29.9 , 29.4 , 29.4 , 29.3 , 29.2 , 29.0 , 27.0 , 25.7 , 24.9 , 23.2 , ( m , 4H ) , 1.46-1.26 ( m , 22H ) , 0.88 / 0.87 ( overlapping t , J = 6.8 
22.7 , 14.1 ; HRFAB - MS ( 3 - NBA matrix ) : calcd . for Hz , total 3H ) . 
C27H4303C12 : 485.2589 [ M + H ] * . Found : 485.2572 . Small quantities of individual isomers could be separated 
first - eluting trans : R = 0.28 ; IR ( ZnSe , cm ' ) 3449 , 3028 , for analysis by HPLC using 10 % EtOAc / Hex . The stereo 
2920 , 2850 , 1736 , 1456 , 1157 , 696 cm- ' ; ' H NMR : 8 chemical assignments were confirmed by 2D - NMR experi 
7.37-7.32 ( 5H ) , 5.12 ( s , 2H ) , 3.99 ( ddd , J = 10.0 , 8.4 , 1.2 Hz , ments and by preparation of individual methanesulfonates 
1H , CH OH , trans to the backbone assigned based on from individual samples of alchols described in the previous 
2D - NOESY analysis and 4J diagonal 11.2 Hz ) , 2.68-2.64 ( m , 60 step . 
1H ) , 2.52 ( d , J = 10.0 Hz , 1H , OH ) , 2.34 ( t , J = 7.6 Hz , 1H ) , First eluting trans : R - 0.31 ; IR ( ZnSe , cm - 1 ) 3032 , 2926 , 
2.29-2.20 ( m , 1H ) , 1.67-1.26 ( br m , 27H ) , 0.88 ( app t , J = 6.8 2855 , 1737 , 1733 , 1456 , 1180 , 697 cm ' ; ' H NMR : 8 
Hz , 3H ) ; 13C NMR 8 173.6 , 136.1 , 128.5 ( two overlapping 7.37-7.32 ( 5H ) , 5.12 ( s , 2H ) , 4.84 ( d , J = 7.6 Hz , 1H ) , 3.20 ( s , 
signals ) , 128.2 ( two overlapping signals ) , 91.1 , 82.6 , 66.1 , 3H ) , 2.74-2.68 ( m , 2H ) , 2.36 ( t , J = 7.6 Hz , 2H ) , 1.67-1.32 ( br 
50.3 , 44.4 , 34.3 , 31.9 , 29.7 , 29.5 , 29.2 , 29.04 , 29.02 , 28.4 , 65 m , 26H ) , 0.88 ( t , J = 6.8 Hz , 3H ) ; 13C NMR 8 173.6 , 136.1 , 
28.23 , 28.15 , 27.7 , 24.9 , 22.7 , 14.1 ; ESI - MS : calcd . for 128.5 ( two overlapping signals ) , 128.2 ( two overlapping 
C27H4203C12Na : [ M + Na ] +507.2409 . Found : 507.2422 . signals ) , 86.4 , 85.8 , 66.1 , 50.5 , 41.1 , 39.5 , 34.3 , 31.8 , 29.5 , 
on 
55 
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29.4 , 29.3 , 29.2 , 29.01 , 28.98 , 28.3 , 28.1 , 27.6 , 27.1 , 24.9 , d 180.6 , 140.0 , 139.9 , 46.8 , 46.7 , 34.1 , 31.9 , 29.9 , 29.8 , 29.8 , 
22.6 , 14.1 ; ESI - MS : calcd . for C28H40 , C1 , S : [ M + Na ] * 29.7 , 29.6 , 29.5 , 29.3 , 29.3 , 29.2 , 29.0 , 28.3 , 28.2 , 24.6 , 22.7 , 
585.2184 . Found : 585.2188 . 14.1 ; HRFAB - MS ( Gly matrix ) : calcd . for C20H3502 
Second - eluting trans : R = 0.26 ; IR ( ZnSe , cm ) 3040 , 307.2637 . Found [ M - H ] " : 307.2636 . Purity > 99 % by HPLC 
2927 , 2855 , 1734 , 1456 , 1179 , 697 cm - ; 1H NMR : 8 5 ( retention time , 4.63 min ) . 
7.37-7.32 ( m , 5H ) , 5.11 ( s , 2H ) , 4.84 ( dd , J = 8.4 , 0.8 Hz , 1H ) , cis - 9,10 - Ethanooctadecanoic acid ( 2 ) . A solution of 
3.19 ( s , 3H ) , 2.76-2.65 ( m , 2H ) , 2.35 ( t , J = 7.6 Hz , 2H ) , cyclobutene 1 ( 0.031 g , 0.1 mmol ) and 10 % Pd / C ( 0.02 g , 
1.67-1.32 ( 26H ) , 0.89 ( t , J = 6.8 Hz , 3H ) ; 13C NMR & 173.6 , 0.02 mmol ) in EtoAc ( 1 mL ) was placed in a vial under an 
136.1 , 128.5 ( two overlapping signal ) , 128.2 ( two overlap atmosphere of H , and stirred at rt overnight ( 16 h ) . The 
ping signal ) , 86.4 , 85.7 , 66.1 , 50.5 , 41.1 , 39.5 , 34.3 , 31.8 , 10 mixture was then filtered through a plug of Celite and the 
29.6 , 29.31 , 29.25 , 29.2 , 29.0 , 28.3 , 28.1 , 27.6 , 27.0 , 24.9 , plug was washed with approximately 10 mL of EtOAc . The 
22.7 , 14.1 : ESI - MS ; calcd . for C28H4403C12S : [ M + Na ] * solution was then evaporated under vacuum to afford 0.0297 
585.2184 . Found : 585.2205 . g of the unprotected acid 2 ( 96 % ) as a colorless oil which 
First - eluting cis : R , -0.26 ; IR ( ZnSe , cm ' ) 2926 , 2855 , was pure enough to use without chromatography : R = 0.50 
1736 , 1456 , 1182 , 697 cm- ?; H NMR : 87.37-7.32 ( m , 5H ) , 15 ( 80 : 20 : 1 of Hex : EtOAC : ACOH ) ; IR ( ZnSe , cm ) : 3051 ( br ) , 
5.33 ( app d , J = 9.6 Hz , 1H ) , 5.11 ( s , 2H ) , 3.19 ( s , 3H ) , 2921 , 2852 , 1708 cm - 1 ; H NMR : 810.93 ( br s , 1H , COOH ) , 
2.80-2.72 ( bm , 2H ) , 2.36 ( app t , J = 7.6 Hz , 2H ) , 1.70-1.63 2.35 ( t , J = 7.3 , 2H ) , 2.24 ( br s , 2H ) , 2.00-1.90 ( br m , 1H ) , 
( rn , 4H ) , 0.87 ( t , J = 6.8 Hz , 3H ) ; 13C NMR 8 173.6 , 136.0 , 1.64 ( quintet J = 7.3 , 2H ) , 1.60-1.50 ( m , 2H ) , 1.45-1.10 ( br m , 
128.5 ( two overlapping signal ) , 128.1 ( two overlapping 24H ) , 0.88 ( br t , J = 7.0 Hz , 3H ) ; 13C NMR : 8 180.2 , 37.7 , 
signal ) , 88.9 , 80.7 , 66.0 , 49.5 , 40.2 , 39.2 , 34.2 , 31.8 , 29.7 , 20 37.6 , 34.1 , 31.9 , 30.11 , 30.05 , 29.9 , 29.7 , 29.7 , 29.4 , 29.3 , 
29.3 , 29.3 , 29.2 , 29.0 , 28.8 , 26.7 , 25.7 , 24.8 , 23.7 , 22.6 , 29.1 , 27.64 , 27.55 , 24.8 , 24.7 , 22.7 , 14.1 ; HRCI - MS : calcd . 
14.1 : HRFAB - MS ( 3 - NBA matrix ) : calcd . for for C20H3802 : [ M + H ] * 311.2950 . Found : 311.2949 . Purity 
C28H4503C12S : [ M + H ] +563.2365 . Found : 563.2349 . 100 % by HPLC ( retention time , 4.56 min ) . 
Second - eluting cis : R , -0.21 ; IR ( ZnSe , cm- ? ) 2925 , 2855 , 2- ( Octanoic acid benzyl ester , 8 - yl ) 3 - octylcyclobutanone 
1735 , 1457 , 1181 , 697 cm- ' ; ' H NMR : 8 7.36-7.32 ( m , 5H ) , 25 and 3- ( Octanoic acid benzyl ester , 8 - yl ) 2 - octylcyclobu 
5.33 ( app d , J = 9.6 Hz , 1H ) , 5.11 ( s , 2H ) , 3.20 ( s , 3H ) , tanone ( OA5 ) was prepared by a modification of a known 
2.80-2.69 ( bm , 2H ) , 2.34 ( app t , J = 7.6 Hz , 2H ) , 1.74-1.60 procedure ( see Powers , D. C. et al . J Org . Chem . 2007 , 72 , 
( 4H ) , 1.50-1.19 ( 22H ) ; 13C NMR 8 173.6 , 136.1 , 128.5 ( two 187-194 ) . To a solution of the regioisomeric dichloroketones 
overlapping signal ) , 128.1 ( two overlapping signal ) , 89.0 , OA2 ( 0.67 g , 1.4 mmol ) in glacial acetic acid ( 3 mL ) was 
80.7,66.0 , 49.5 , 40.2 , 39.3 , 34.2 , 31.8 , 29.5 , 29.5 , 29.3 , 29.2 , 30 added Zn ( Cu ) ( 0.45 g , 6.9 mmol ) . The mixture was stirred 
28.9 , 28.9 , 28.7 , 26.8 , 25.7 , 24.8 , 23.7 , 22.6 , 14.1 ; HRFAB at rt under N , until TLC showed complete disappearance of 
MS ( 3 - NBA matrix ) : calcd . for C28H450 , C12S : [ M + H ] * stating material ( ~ 5 h ) . The reaction mixture was then 
563.2365 . Found : 563.2360 . filtered through a plug of Celite and washed with ether . The 
1- ( Octanoic acid , 8 - yl ) -2 - octylcyclobutene ( 1 ) was pre filtrate was washed sequentially with saturated NaHCO3 
pared from the unpurified dichloromethanesulfonate using a 35 and water , and dried over Na2SO4 . The residue obtained 
reported procedure ( see Baldwin , J. D. and Belfield , K. D. J upon concentration was purified by flash chromatography on 
Org . Chem . 1987 , 52 , 4772-4776 ; and Powers , D. C. et al . silica gel ( 5 % EtoAc in Hex ) to afford 0.388 g ( 87 % ) of a 
J. Org . Chem . 2007 , 72 , 187-194 ) . NH3 ( ~ 15 mL , liquid ) mixture of regioisomeric cyclobutanones OA5 as a colorless 
was condensed into a 100 - mL three - necked round bottom oil : R = 0.41 ( 10 % EtOAc / Hex ) ; IR ( ZnSe , cm ' ) 3034 , 
flask fitted with a dry ice / acetone condenser . Sodium ( 0.1127 40 2923 , 2853 , 1774 , 1735 , 1161 , 696 cm - 1 ; H NMR : 8 
g , 4.90 mmol , sliced under Hex ) was added in small pieces . 7.36-7.26 ( br m , 5H ) , 5.115 ( s , 2H ) , 3.28-3.17 ( br m , 1H ) , 
The resulting deep blue solution was stirred for 20 min . A 3.15-3.05 ( br m , 1H ) , 2.51-2.43 ( m , 1H ) , 2.42-2.32 ( br m , 
solution of 0.2761 g ( 0.49 mmol ) of the mixture of regioi 1H ) , 2.35 / 2.34 ( overlapping t , J = 7.53 Hz , 2H ) , 1.70-1.50 ( br 
someric methanesulfonates S3 in anhydrous THF ( 1.5 mL ) m , 4H ) , 1.45-1.14 ( br m , 22H ) , 0.88 / 0.87 ( overlapping t , 
was added over 10 min . The reaction was removed from the 45 J = 7.19 Hz , 3H ) ; 13C NMR 8 212.0 , 173.6 , 136.1 , 128.5 , 
dry ice bath and allowed to stir at -35 ° C. ( refluxing NH3 ) 128.1 , 66.0 ( br s ) , 61.9761.8 ( two app s ) , 50.1 / 50.1 ( two app 
5-30 min ( depending on the scale of preparation ) . The s ) , 34.2 , 31.8 , 30.1 , 30.0 , 29.6 , 29.6 , 29.5 , 29.4 , 29.4 , 29.23 , 
reaction was then recooled to -78 ° C. ( dry ice / acetone ) and 29.17 , 29.0 , 28.2 , 28.08 , 28.05 , 27.98 , 27.6 , 24.9 , 24.3 , 24.3 , 
stirred for 2 h or until the starting material was consumed by 22.6 , 14.1 ; HREI - MS : calcd . for C27H4,03Na , 437.3032 . 
TLC . Saturated aq . NH4Cl was slowly added until the blue 50 Found [ M + Na ] * : 437.3029 . 
color was no longer visible . The condenser was removed and 2- ( Octanoic acid , 8 - yl ) 3 - octylcyclobutanone and 3- ( oc 
the reaction mixture was slowly allowed to warm to 0 ° C. tanoic acid , 8 - yl ) 2 - octylcyclobutanone ( 3 ) . A solution of the 
with evaporation of NHz . The remaining reaction mixture cyclobutanone OA5 ( 0.0391 g , 0.09 mmol ) and 10 % Pd / C 
was diluted with 30 mL of water and the suspension was ( 0.020 g , 0.18 mmol ) in anhydrous MeOH ( 1 mL ) in a vial 
extracted with CH2Cl2 ( 3x50 mL ) . The organic layers were 55 was placed under an atmosphere of H , and stirred at rt 
combined and washed sequentially with 1N aq . HCl / water / overnight ( 16 h ) . The mixture was then concentrated under 
saturated aq . NaHCO3 / water / brine . The organic solution vacuum . The residue was resuspended in EtOAC ( ~ 20 mL ) 
was then dried with NaSO4 , and concentrated under reduced and filtered through a plug of Celite . The residue obtained 
pressure . The residue was purified by flash column chroma upon concentration was purified by flash column chroma 
tography using 10 % EtOAc / Hex to afford the cyclobutene 60 tography on silica gel ( 10 % / 25 % Eto Ac / Hex ) to afford 
carboxylic acid ( 0.1312 g , 87 % ) as a low - melting white 0.0267 g of the carboxylic acid 3 ( 87 % ) as a colorless oil : 
solid : R20.50 ( 80 : 20 : 1 of Hex : EtOAc : ACOH ) ; mp = 33-35 ° R = 0.16 ( 25 % EtOAc / Hex ) ; IR ( ZnSe , cm ) 3322 ( br ) , 
C .; IR ( ZnSe , cm- ? ) 3493 , 3036 , 2923 , 2853 , 1708 , 1467 , 2926 , 2856 , 1776 , 1709 , 913 , 749 cm - ; ' H NMR : 8 
1275 , 728 cm ' ; ' H NMR : 8 10.94 ( br s , 1H , COOH ) , 3.28-3.18 ( br m , 1H ) , 3.13 / 3.09 ( overlapping dd , J = 9.6 , 3.1 
6.17-6.15 ( br m , 2H ) , 2.83-2.75 ( br s , 2H ) , 2.35 ( t , J = 7.6 Hz , 65 and 9.0 , 3.5 , 0.56H / 0.44H ) , 2.50 / 2.46 ( two app abnormal 
2H ) , 1.68-1.60 ( br m , 2H ) , 1.52-1.40 ( br m , 2H ) , 1.35-1.20 shape quintets , 0.55H / 0.52H ) , 2.42 ( br dd , J = 9.6 , 4.5 Hz , 
( 23H ) , 0.88 ( t , J = 6.8 Hz , 3H ) ; 13C NMR ( found 18 carbons ) 1H ) , 2.35 / 2.34 ( two app t , J = 7.45 Hz , 2H ) , 1.63-1.54 ( br m , 
aq . 
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4H ) , 1.43-1.18 ( br in , 22H ) , 0.88 / 0.87 ( overlapping br t , 4 - octylcyclobutanone ( OA7 ) was prepared based on a modi 
J = 7.0 Hz , 3H ) ; 13C NMR : 8 212.1 , 179.9 , 62.0 / 61.9 ( two fication of a known procedure . To a solution of dichloroke 
app s ) , 50.20 / 50.17 ( two app s ) , 34.0 , 31.9 , 30.1 , 30.1 , 29.7 , tone OA2 ( 0.9917 g , 2.1 mmol ) in 4 mL of glacial acetic acid 
29.6 , 29.6 , 29.4 , 29.3 , 29.2 , 29.02 , 28.98 , 28.2 , 28.1 , was added Zn dust ( 0.1475 g , 23 mmol ) . [ Note : The amount 
28.0 , 27.6 , 24. , 24.3 , 24.3 , 22.7 , 14.1 ; HREI - MS : calcd . 5 of Zn required depended upon the purity of the dichlorocy 
for C20H360 Na , 347.2557 . Found [ M + Na ] " : 347.2557 . clobutanone . In most cases , it was necessary to add a second 
Purity > 97 % by HPLC ( retention time , 6.82 min ) . equivalent after approximately 12 h of reaction . ] The mix 
2- ( Octanoic acid benzyl ester , 8 - yl ) 3 - octylcyclobutanol ture was stirred at rt under N2 until complete disappearance 
and 3- ( Octanoic acid benzyl ester , 8 - yl ) 2 - octylcyclobutanol of the starting material was observed ( 16 h , TLC ) . The 
( OA ) . To a -10 ° C. ( ice / NaCl bath ) solution of the cyclobu- 10 reaction mixture was then cooled in an ice bath and diluted 
tanone OA5 ( 0.037 g , 0.07 mmol ) in anhydrous MeOH ( 1.5 with water ( 20 mL ) . The resulting solution was extracted 
mL ) was added NaBH4 ( 0.005 g , 0.15 mmol ) under N2 . The with EtOAC ( 3x50 mL ) and the combined organic layers 
reaction mixture was stirred at -10 ° C. until no starting were washed sequentially with water ( 2x100 mL ) and 
material remained on TLC ( 20 min ) . The reaction was saturated NaHCO3 solution ( 2x50 mL ) . The resulting 
diluted with about 5 mL CH2Cl2 and quenched with 2 mL 15 organic layer was dried over Na2SO4 and concentrated under 
sat . NaHCO3 . The mixture was stirred for 10 min . The reduced pressure to furnish a colorless oil ( 0.8948 g , 97 % 
organic layer was removed and the aqueous layer was crude yield ) as a 1 : 1 mixture of regioisomers , each a 9 : 1 
extracted with CH C12 ( 3x5 mL ) . The organic layers were mixture of cis / trans stereoisomers ( ' H NMR ) ; the mixture 
combined , dried over with Na2SO4 , and evaporated to afford was used directly in the next step . Analysis of the ' H NMR 
the alcohol as a colorless oil ( 0.029 g , 99 % ) . Although the 20 indicated that the expected product was accompanied by 
crude product appears pure by ' H NMR , it is actually a recovered starting material OA2 ( approximately 14 % ) and 
mixture of two regioisomers , each a 70:30 mixture of the the cyclobutanone OA5 ( overreduction product , approxi 
1,2,3 - cis / cis and the 1,2 - trans - 2,3 - cis isomers ( isomer iden mately 10 % ) . These byproducts could not be removed by 
tities established through 2D - NMR ) . The individual isomers flash chromatography . R = 0.58 / 0.53 ( major ) , 0.48 / 0.43 ( mi 
can be detected by TLC in 20 % EtOAc / Hex : R = 0.50 25 nor ) ( 10 % EtoAc in Hex ) ; IR ( ZnSe , cm ! ) 3036 , 2925 , 
( major , all cis ) , 0.45 ( major , all cis ) , 0.39 ( minor , OH is trans 2854 , 1789 , 1735 , 1456 , 1162 , 696 cm- ' ; ' H NMR : 8 
to backbone ) , and 0.37 ( minor , OH is trans to backbone ) ; IR 7.36-7.25 ( m , 5H ) , 5.12 / 5.11 ( overlapping s , 2H ) , 4.97 ( dd , 
( ZnSe , cm- ? ) 3396 ( br ) , 2922 , 2852 , 1737 , 1156 , 732 , 696 J = 2.6 , 9.5 , 0.1H ) , 4.51 ( dd , J = 2.8 , 7.6 Hz , 0.9H ) , 3.35-3.20 
cm- ' ; ' H NMR : 8 7.39-7.28 ( br m , 5H ) , 5.14 ( s , 2H ) , 4.23 ( m , 1.1H ) , 2.75-2.65 ( m , 0.1H ) , 2.53-2.40 ( m , 0.9H ) , 2.36 / 
br q , J = 7.3 , 0.714 ) , 3.93 ( br q , J = 7.3 , 0.3H ) , 2.42-2.36 30 2.35 ( overlapping t , J = 7.2 Hz , 2H ) , 1.75-1.20 ( m , 26H ) , 
( overlapping signal , 1H ) , 2.37 ( t , J = 7.6 , 2H ) , 2.15-1.95 ( br 0.92-0.85 ( m , 3H ) ; 13C NMR 8 203.48 / 203.45 , 173.5 , 136.1 , 
m , 1H ) , 1.90-1.78 ( br m , 1H , ) , 1.70-1.60 ( br m , 2H ) , 128.5 , 128.1 , 66.0 , 65.7 , 58.3 , 58.2 , 40.74 / 40.72 , 34.18 , 
1.60-1.48 br m , 2H ) , 1.45-1.20 ( br m , 22H ) , 0.90 ( br t , J = 7.6 , 31.77 / 31.75 , 29.5 , 29.3 , 29.24 , 29.16 , 29.14 , 29.13 , 29.02 , 
2H ) ; 13C NMR : 8 173.68 / 173.65 ( overlapping ) , 136.1 , 28.97 , 28.90 , 28.86 , 28.02 , 27.96 , 27.92 , 27.87 , 25.64 / 25.57 , 
128.5 , 128.1 , 72.2 , 66.09 / 66.06 ( two overlapping s ) , 66.0 , 35 24.80 / 24.78 , 22.59 / 22.58 , 14.0 ; HRESI - MS : calcd . for 
43.97 / 43.95 ( overlapping ) , 37.3 , 34.3 , 31.9 , 30.7 , 30.6 , 30.2 , C27H4102C1Na , 471.2642 . Found [ M + Na ] * : 471.2635 . 
29.94 , 29.87 , 29.8 , 29.7 , 29.62 , 29.58 , 29.5 , 29.33 , 29.29 , 2 - Chloro - 4- ( octanoic acid , 8 - yl ) 3 - octylcyclobutanone- ; 
29.2 , 29.14 , 29.08 , 29.0 , 27.7 , 27.6 , 24.90 , 24.88 , 23.4 , 23.3 , 2 - Chloro - 3- ( octanoic acid , 8 - yl ) 4 - octylcyclobutanone ( 5 ) 
22.7 , 14.1 ; HRESI - MS : calcd . for C27H4403Na , 439.3188 . was prepared in a similar manner as compound 2. The 
Found [ M + Na ] + : 439.3174 . 40 benzyl ester OA7 ( 0.085 g , 0.19 mmol ) , 10 % Pd / C ( 0.040 g , 
2- ( Octanoic acid , 8 - yl ) 3 - octylcyclobutanol and 3- ( Oc 0.038 mmol ) and EtOAC ( 1.9 mL ) were used to afford 
tanoic acid , 8 - yl ) 2 - octylcyclobutanol ( 4 ) were prepared as 0.0478 g of the unprotected acid 5 ( 70 % ) as a colorless oil 
a mixture ( 0.0158 g , 81 % ) from benzyl ester ( s ) OA6 ( 0.0247 after purification by flash column chromatography ( 20 % 
g , 0.06 mmol ) , 10 % Pd / C ( 0.0126 g , 0.012 mmol ) and EtOAc / Hex ) . The product also contain approximately 5 % of 
EtOAc ( 0.6 mL ) using a similar procedure as described for 45 an inseparable trans - chlorocyclobutanone 7 byproduct ( ' H 
compound 2. Although the product , which is a colorless oil , NMR signal at 8 4.37 ) probably arising from the epimeriza 
is assumed to be a similar mixture of regio- and stereoiso tion of cis - chlorocyclobutanone 5 : R , 0.19 ( 4 : 1 Hex : E 
mers as was present in the benzyl ester precursor , the TOAc ) ; IR ( ZnSe , cm- ? ) 3036 , 2924 , 2854 , 1788 , 1706 , 1461 
individual isomers are not separable : R = 0.32 ( 4 : 6 : 0.05 of cm - 1 ; + H NMR : d 10.74 ( br s , 1H , COOH ) , 4.96 ( dd , J = 9.4 , 
EtOAc : Hex : AcOH ) ; IR ( ZnSe , cm- ? ) 3309 ( br ) , 2922,2853 , 50 2.6 , 0.05H ) , 4.50 ( dd , J = 7.6 , 2.8 , 0.95H ) , 3.35-3.20 ( m , 
1709 cm - 1 ; ' H NMR : 8 4.22 ( 9 , J = 7.6,0.7H , assumed OH 1.05H ) , 2.46 ( quintet , J = 8.1 , 0.95H ) , 2.74-2.62 ( m , 0.05H ) , 
is cis to backbone from the characterization of starting 2.35 / 2.33 ( overlapping t , J = 7.3 , 2H ) , 1.80-1.15 ( m , 22H ) , 
material ) , 3.92 ( q , J = 7.6 , 0.3H , assumed OH is trans to 0.88 / 0.87 ( overlapping t , J = 6.9 , 3H ) ; 13C NMR 8 203.62 / 
backbone ) , 2.43-2.33 ( br m , 1H ) , 2.34 ( t , J = 7.3 , 2H ) , 2.18 203.56 , 180.1 , 65.7 , 58.30 / 58.26 , 401.8 , 34.0 , 31.8 , 29.5 , 
1.92 ( m ) , 1.84 ( br septet , J = 8.0 , 1H ) , 1.68-1.58 ( br quintet , 55 29.4 , 29.3 , 29.18 / 29.15 , 29.04 / 29.00 , 28.9 , 28.04 / 27.98 , 
J = 7.0 , 2H ) , 1.58-1.48 ( br m , 2H ) , 1.43-1.18 ( br m , 22H ) , 27.95 / 27.90 , 25.67 / 25.59 , 24.5 , 22.6 , 14.1 ; HRESI - MS : 
0.88 ( br t , J = 7.0 Hz , 3H ) ; 13C NMR : 8 179.50 / 179.46 ( two calcd . for C20H3502C1Na , 381.2172 . Found [ M + Na ] * : 
app s ) , 72.28 , 66.16 / 66.12 ( two app s ) , 48.87 / 48.79 ( two app 381.2191 . 
s ) , 43.97 , 37.26 , 35.06 , 33.98 , 31.89 , 30.69 / 30.62 , 30.24 , ( E ) -9 - octadecenoic acid , benzyl ester ( benzyl elaidate ) 
30.18 , 29.90 , 29.87 , 29.79 , 29.74 , 29.63 , 29.60 , 29.51 , 60 was prepared from the reaction of elaidic acid ( 0.9836 , 3.5 
29.46 , 29.34 , 29.31 , 29.21 , 29.11 , 29.06 , 29.01 , 28.99 , mmol ) , DCC ( 0.79 g , 3.8 mmol ) , DMAP ( 0.087 g , 0.7 
28.97 , 28.67 , 28.60 , 28.05 , 27.95 , 27.92 , 27.73 , 27.60 , mmol ) , and benzyl alcohol ( 0.73 mL , 7 mmol ) in CH2Cl2 
24.66 / 24.63 , 23.38 / 23.34 , 22.67 , 14.10 ; HRESI - MS : calcd . ( 10 mL ) by a similar procedure as employed for benzyl 
for C20H3 : 03Na , 349.2719 . Found [ M + Na ] * : 349.2715 . oleate . The product was purified by flash column chroma 
Purity > 99 % by HPLC ( retention time , 11.8 and 15.9 min ) . 65 tography on silica gel ( 2.5 % / 5 % EtOAc / Hex ) to afford 
2 - Chloro - 4- ( octanoic acid benzyl ester , 8 - yl ) -3 - octylcy 1.2280 g ( 95 % ) of benzyl elaidate as a colorless oil : Rf = 0.57 
clobutanone ; 2 - Chloro - 3- ( octanoic acid benzyl ester , 8 - yl ) ( 10 % EtOAc / Hex ) . IR ( ZnSe , cm - 1 ) 2922 , 2852 , 2737 , 
15 
H1 , OH 
H1 , H4 ( trans ) H1 , H3 ( cis ) 
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1160 , 966 , 696 cm- ' ; ' H NMR : 8 7.38-7.34 ( m , 5H ) , 31.9 , 31.3 , 29.7 , 29.5 , 29.4 , 29.3 , 29.0 , 27.7 , 27.5 , 26.6 , 24.9 , 
5.41-5.38 ( m , 2H ) , 5.13 ( s , 2H ) , 2.37 ( t , J = 7.2 Hz , 2H ) , 1.98 22.7 , 14.1 ; HRESIMS : calcd . for C2H400 , C12 : [ M + Na ] * 
( br s , 4H ) , 1.68-1.63 ( m , 2H ) , 1.38-1.18 ( br m , 20H ) , 0.90 507.2409 . Found : 507.2409 . 
( t , J = 7.2 Hz , 3H ) ; 13C NMR 8 173.6 , 136.1 , 130.4 , 130.2 , first - eluting H. - H , cis : R = 0.61 ; IR ( ZnSe , cm ) : 3448 
128.5 , 128.1 , 66.0 , 34.3 , 32.57 , 32.52 , 31.9 , 29.6 , 29.52 , 5 ( br ) , 2925 , 2854 , 1737 , 1456 , 1163 , 734 , 697 cm - l ; ' H 
29.46 , 29.3 , 29.2 , 29.1 , 29.0 , 28.9 , 24.9 , 22.7 , 14.1 . NMR : 8 7.37-7.31 ( m , 5H ) , 5.12 ( s , 2H ) , 3.91 ( dd , 
2,2 - Dichloro - 4- ( octanoic acid benzyl ester , 8 - yl ) 3 - octyl J 11.02-10.8 Hz , 211,14 ( trans ) = 8.0 Hz , 4J11 , H3 ( cis ) = 0 Hz , 
cyclobutanone- ; 2,2 - Dichloro - 3- ( octanoic acid benzyl ester , 1H , CH - OH ) , 2.46 ( d , J = 10.8 Hz , 2H , OH ) , 2.36 ( t , J = 7.6 
8 - yl ) 4 - octylcyclobutanone ( EA2 ) was prepared based on a Hz , 2H ) , 2.11-2.04 ( m , 1H , CH CCl2 ) , 1.75-1.18 ( m , 27H ) , 
known procedure . To a mixture of Zn ( Cu ) ( 1.8443 , 28 10 0.88 ( t , J = 6.8 Hz , 3H ) ; 13C NMR , 75 MHz : 8 173.6 , 136.1 , 128.5 , 128.2 , 91.0 , 81.6 , 66.1 , 51.9 , 48.1 , 34.3 , 33.0 , 31.8 , mmol ) and benzyl elaidate EA1 ( 2.073 g , 5.6 mmol ) in 11 30.0 , 29.6 , 29.41 , 29.38 , 29.2 , 29.0 , 27.3 , 26.8 , 24.9 , 22.6 , mL of anhydrous ether was added over 2 h ( syringe pump ) 14.1 ; HRESIMS : calcd . for C27H4003C12 : [ M + Na ] * trichloroacetyl chloride ( 2.0 mL , 18 mmol ) . The reaction 507.2409 . Found : 507.2415 . 
mixture was stirred at rt for 5 h ( or until the starting material Second - eluting H. - H , trans : R = 0.56 ; IR ( ZnSe , cm ' ) : is consumed by TLC ) and filtered through a plug of Celite . 3463 ( br ) , 2925 , 2854 , 1736 , 1456 , 1163 , 696 cm ; ' H 
The residue was washed with ether ( 20 mL ) . The combined NMR : d 7.36-7.31 ( m , 5H ) , 5.11 ( s , 2H ) , 4.40-4.34 ( m , 1H ) , ether layers were transferred to a round bottom flask and 2.64-2.55 ( m , 1H , CH - OH ) , 2.64-2.55 ( m , 1H , CH 
cooled over ice . The black solution was then diluted with 40 CCl2 ) , 2.46 ( d , J = 4.8 Hz , 1H , OH ) , 2.35 ( t , J = 7.6 Hz , 2H ) , 
mL of water and 40 mL of sat . NaHCO3 . The mixture was 20 2.20-2.03 ( m , 1H , CH - CHOH ) , 1.80-1.10 ( br m , 26H ) , 
allowed to warm to rt and stirred overnight . The aqueous 0.88 ( t , J = 6.4 Hz , 3H ) ; 13C NMR , 75 MHz : 8 173.7 , 136.1 , 
layer was extracted with ether ( 3x50 mL ) and the combined 128.5 , 128.2 , 90.2 , 78.4 , 66.1 , 57.0 , 42.0 , 34.3 , 31.9 , 31.3 , 
organic layers were dried over Na2SO4 and evaporated to 29.6 , 29.5 , 29.41 , 29.39 , 29.2 , 29.1 , 29.0 , 27.6 , 27.5 , 26.7 , 
dryness . The residue obtained upon concentration could be 24.9 , 22.7 , 14.1 ; HRESIMS : calcd . for C27H4003Cl2 : 
used for the next step without further purification or , alter- 25 [ M + Na ] +507.2409 . Found : 507.2398 . 
natively , could be purified by rapid flash column chroma Second - eluting H. - H , cis : R = 0.51 ; IR ( ZnSe , cm- ' ) ; 
tography through a short plug of silica ( 2.5 % / 5 % EtoAc / 3444 ( br ) , 2924 , 2854 , 1734 , 1162 , 734 , 696 cm - 1 ; 1H NMR : 
Hex ) to afford 1.6856 g ( 63 % ) of a yellow oil consisting of ( 57.37-7.31 ( m , 5H ) , 5.11 ( s , 2H ) , 3.90 ( dd , 3J , = 10.8 
a 1 : 1 mixture of regioisomers : R = 0.63 ( 20 % EtOAc / Hex ) ; Hz , 3J  = 8.0 Hz , 4J = 0 Hz , 1H , CH - OH ) , 
IR ( ZnSe , cm - 1 ) 2926 , 2855 , 1802 , 1735 , 1456 , 1162 , 696 30 2.52 ( OH , d , J = 10.8 Hz , 2H ) , 2.35 ( t , J = 7.6 Hz , 2H ) , 
cm ' ; ' H NMR : 8 7.47-7.23 ( m , 5H ) , 5.120 / 5.117 ( overlap 2.13-2.02 ( in , 1H , CH - CC12 ) , 1.75-1.18 ( m , 27H ) , 0.89 ( t , 
ping s , 2H ) , 3.158 / 3.126 ( overlapping dt , J = 7.2 , 1.5 Hz , 1H ) , J = 6.8 Hz , 3H ) ; 13C NMR , 75 MHz : 8 173.7 , 136.1 , 128.5 , 
2.56-2.46 ( m , 1H ) , 2.37 / 2.34 ( overlapping t , J = 7.6 Hz , 2H ) , .1 , 91.0 , 81.6 , 66.1 , 51.9 , 48.0 , 33.0 , 31.8 , 30.0 , 
1.96-1.18 ( m , 26H ) , 0.90 / 0.87 ( overlapping t , J = 7.2 Hz , 3H ) ; 29.6 , 29.4 , 29.3 , 29.2 , 29.02 , 28.97 , 28.9 , 27.2 , 26.8 , 24.9 , 
13C NMR , 75 MHz : d 196.3 , 173.5 , 136.0 , 128.4 , 128.1 , 35 24.8 , 22.6 , 14.1 ; HRESIMS : calcd . for C2 H4002Cl2 : 
87.1 , 66.0 , 60.7 , 60.6 , 52.3 , 34.2 , 34.1 , 31.8 , 31.7 , 31.37 , [ M + Na ] 507.2409 . Found : 507.2409 . 
31.36 , 29.42 , 29.40 , 29.3 , 29.23 , 29.20 , 29.14 , 29.12 , 29.08 , 2,2 - Dichloro - 4- ( octanoic acid benzyl ester , 8 - yl ) 3 - octyl 
28.93 , 28.90 , 28.85 , 27.5 , 27.4 , 27.12 , 27.05 , 24.80 , 24.78 , cyclobutanol , methanesulfonate ester ; 2,2 - Dichloro - 3- ( oc 
22.59 , 22.57 , 14.04 , 14.03 ; HRESI - MS : calcd . for tanoic acid benzyl ester , 8 - yl ) 4 - octylcyclobutanol , meth 
C2H400 , C1 , Na [ M + Na ] * : 505.2252 Found : 505.2248 . 40 anesulfonate ester ( EA4 ) was prepared similarly to OA4 
2,2 - Dichloro - 4 - octanoic acid benzyl ester , 8 - yl ) 3 - octyl from reaction of methanesulfonyl chloride ( 0.05 mL , 0.7 
cyclobutanol ; 2,2 - Dichloro - 3- ( octanoic acid benzyl ester , mmol ) , cyclobutanol EA3 ( 0.1659 g , 0.3 mmol ) , and trieth 
8 - yl ) 4 - octylcyclobutanol ( EA3 ) was prepared by a similar ylamine ( 0.20 mL , 1.7 mmol ) in CH2C12 ( 2 mL ) . The crude 
procedure as OA3 . Dichlorocyclobutanone EA2 ( 0.2100 g , product was purified by flash chromatography ( 5 % EtOAc / 
0.4 mmol ) , NaBH4 ( 0.055 g , 1.5 mmol ) , and iProH 6 mL 45 Hex ) to provide dichloro mesylate EA4 as a light yellow oil 
was obtained the product purified by flash column chroma ( 0.1456 g , 86 % ) which included several inseparable iso 
tography with 5 % EtOAc / Hex to afford the mixture of 1 : 1 mers : R = 0.40 / 0.38 ( 20 % EtOAc / Hex ) ; IR ( ZnSe , cm- ) : 
regioisomer EA3 0.1659 g ( 85 % ) as a colorless oil : R , -0.66 2925 , 2851 , 1734 , 1368 , 1180 , 964 , 697 cm- ?; H NMR : 8 
( minor ) /0.61 ( major ) /0.56 ( minor ) /0.51 ( major ) ( 10 % 7.38-7.30 ( m , 5H ) , 5.20 ( dd , J = 7.1 , 1.2 Hz , 0.4H ) , 5.115 / 
EtOAc / Hex ) . IR ( ZnSe , cm- ? ) : 3459 ( br ) , 2924 , 2853 , 1736 , 50 5.112 ( two overlapping s , total 2H ) , 4.84 ( d , J = 8.8 Hz , 
1456 , 1161 , 734 , 696 cm- ?; ' H NMR : 87.36-7.31 ( m , 5H ) , 0.6H ) , 3.202 / 3.199 ( two overlapping s , 1.8H ) , 3.166 / 3.163 
5.12 ( s , 2H ) , 4.37 ( br d , J = 6.4 Hz , 0.4H ) , 3.91 ( br d , J = 8.0 ( two overlapping s , total 1.2H ) , 2.66-2.58 ( m , 0.4H ) , 2.40 
Hz , 0.6H ) , 2.80-2.45 ( br m , 211 ) , 2.37 / 2.36 ( overlapping t , 2.30 ( m , 2H ) , 2.21-2.12 ( m , 0.6H ) , 2.10-1.98 ( m 0.6H ) , 
J = 7.6 Hz , 2H ) , 1.80-1.05 ( br m , 26H ) , 0.89 / 0.88 ( overlap 1.80-1.15 ( m , 26.4H ) , 0.91-0.86 ( m , 3H ) ; 13C NMR 8 173.6 , 
ping t , J = 6.7 Hz , 3H ) . Small quantities of individual isomers 55 136.10 / 136.08 , 128.5 / 128.1 , 86.45 / 86.38 , 84.09 , 83.86 / 
could be separated for analysis by flash column chromatog 83.82 , 66.03 / 66.01 , 57.18 , 51.81 / 51.80 , 44.51 / 44.50 , 41.71 , 
raphy using 10 % EtOAc / Hex . The stereochemical assign 39.5 , 39.0 , 34.2 , 32.21 / 32.18 , 31.78 / 31.77 , 31.41 / 31.36 , 
ments were assigned by 2D - NMR experiments including 30.1 , 29.49 29.46 , 29.42 , 29.34 , 29.32 , 29.27 , 29.22 , 29.16 , 
COSY , NOESY , and HSQC . 28.95 , 28.90 , 28.2 , 27.0 , 26.9 , 26.8 , 26.7 , 26.6 , 26.5 , 26.4 , 
first - eluting H , -Hz trans : R = 0.66 ; IR ( ZnSe , cm- ? ) : 3463 60 26.3 , 24.8 , 22.6 , 14.1 ; HRESI - MS : C28H4403C1 , SNa : 
( br ) , 2927 , 2855 , 1738 , 1453 , 1158 cm - l ; ' H NMR : 8 [ M + Na ] 585.2184 . Found : 585.2186 . 
7.37-7.31 ( m , 5H ) , 5.12 ( s , 2H ) , 4.38 ( ddd , ' J , = 6.8 Hz , 1- ( Octanoic acid , 8 - yl ) -2 - octylcyclobutene ( 6 ) was pre 
= 1.3 Hz , 1H , CH - OH ) , 2.62 pared similarly to compound 1 from reductive fragmentation 
2.55 ( m , 1H , CHCC12 ) , 2.44 ( d , ° JH1,01 = 5.1 Hz , OH ) , and deprotection of dichloromethansulfonate EA4 ( 0.1430 , 
2.36 ( t , J = 7.6 Hz , 2H ) , 2.18-2.08 ( m , 1H , CH CHOH ) , 65 0.25 mmol ) in THF ( 1 mL ) , NH3 ( ~ 10 mL ) , Na ( -0.09 g , 4.1 
1.80-1.10 ( br m , 26H ) , 0.89 ( t , J = 6.7 Hz , 3H ) ; 13C NMR : 8 mmol ) . The crude product was purified by flash chromatog 
173.6 , 136.1 , 128.5 , 128.2 , 90.2 , 78.5 , 66.1 , 57.0 , 42.0 , 34.3 , raphy ( 10 % EtOAc / Hex ) to afford the acid 6 ( 0.0352 g , 
H1 , H4 
3J41,0H = 5.1 Hz , 4JH1 H3 ( trans ) 
US 10,538,475 B2 
43 44 
46 % ) as a colorless oil : R = 0.35 ( 60:40 of Hex : EtOAC ) ; IR until the starting material was consumed ( TLC , 24 h ) . The 
( ZnSe , cm- ? ) 3124 , 2923 , 2852 , 1708 , 910 , 736 cm - 1 ; ' H reaction was concentrated and the residue redissolved in 
NMR : 8 6.12 ( br s , 2H ) , 2.35 ( t , J = 7.2 Hz , 2H ) , 2.26 ( t , J = 7.2 toluene ( 400 mL ) and triethylamine ( 8.5 mL ) . The solution 
Hz , 2H ) , 1.64 ( quintet , J = 7.2 Hz , 2H ) , 1.44 ( br m , 4H ) , was stirred for 24 h and washed with water . The aqueous 
1.35-1.20 ( 23H ) , 0.88 ( t , J = 6.8 Hz , 3H ) ; 13C NMR 8 179.7 , 5 layer was then extracted with ether . The combined organic 
139.2 , 139.1 , 50.4 , 50.3 , 34.02 , 33.97 , 31.9 , 29.9 , 29.6 , 29.3 , solution were combined , dried with Na2SO4 , and concen 
29.2 , 29.0 , 28.4 , 28.3 , 24.7 , 22.7 , 14.1 ; HRFAB - MS ( 3 - NBA trated under vacuum . The residue was purified by flash 
matrix ) : calcd . for C20H3502Li2 321.2957 . Found [ M - H + column chromatography on silica gel ( 5-10 % EtoAc in 
2Li ] * : 321.2969 . Purity 100 % by HPLC ( retention time , Hex ) to give benzyl 9 - decenoate DA1 ( 13.1 g , 99 % ) as a 
4.73 min ) . 10 colorless oil : R - 0.40 ( 10 % EtOAc / Hex ) ; IR ( ZnSe , cm ! ) : 
2 - Chloro - 4- ( octanoic acid benzyl ester , 8 - yl ) 3 - octylcy 3072 , 2927 , 2855 , 1734 , 1161 , 908 , 730 cm- ?; ' H NMR : 8 
clobutanone- ; 2 - Chloro - 3- ( octanoic acid benzyl ester , 8 - yl ) 7.38-7.32 ( m , 5H ) , 5.83 ( ddt , J = 17 , 10.2 , 6.6 Hz , 1H ) , 5.14 
4 - octylcyclobutanone EA5 was prepared similarly to the ( s , 2H ) , 5.02 ( ddd , J = 7.6 Hz , 2H ) , 5.00 ( dq , J = 17.0 , 1.7 Hz , 
procedure described for compound OA7 . Reaction of benzyl 1H ) , 4.96 ( d of quintet , J = 10.2 , 1.2 Hz , 1H ) , 2.37 ( t , J = 7.3 
ester EA2 ( 0.50 g , 1.0 mmol ) , Zn ( Cu ) ( 0.0744 g , 1.1 mmol ) 15 Hz , 2H ) , 2.10-2.02 ( br q , J = 7.3 Hz , 2H ) , 1.70-1.63 ( br m , 
and glacial acetic acid ( 2 mL ) furnished , after flash chro 2H ) , 1.41-1.48 ( m , 10H ) ; 13C NMR : 8 173.5 , 138.9 , 136.1 , 
matography ( 5 % EtoAc / Hex ) , trans - monochlorocyclobu 128.4 , 128.1 , 128.0 , 114.1 , 65.9 , 34.2 , 33.7 , 28.99 , 28.97 , 
tanone EA5 ( 0.3126 g , 70 % ) as a colorless oil which 28.8 , 28.7 , 24.8 , 22.6 , 14.0 ; HRESI - MS : calcd . for 
included an equal mix of the 2 - chloro - 4 - octyl and 2 - chloro C17H240 Na : [ M + Na ] * 283.1674 . Found : 283.1671 . 
3 - octyl regioisomers , each of which included both epimers 20 3- ( Octanoic acid , 8 - yl , benzyl ester ) 2,2 - dichlorocyclobu 
at the chloride - bearing carbon : R = 0.42 / 0.39 ( minor ) and tanone DA2 was prepared similarly to compound OA2 and 
0.33 ( major ) ( 10 % EtOAc / Hex ) . afforded ( 13.78 g , 80 % ) as a brown oil from benzyl 9 - de 
The amount of Zn dust varied from 1.1-2.2 equiv ; gen cenoate DA1 ( 12.36 g , 48 mmol ) , trichloroacetyl chloride 
erally , a second equivalent of zinc dust was added to the ( 10.7 mL , 95 mmol ) , and Zn ( Cu ) ( 15.55 g , 238 mmol ) in 
incomplete reaction mixture after stirring for approximately 25 ether 0.1 M ( 340 mL ) ( Consistent with a previous report , 
12 h . The residual dichlorocyclobutanone was easily only one isomer was observed . The assignment was con 
removed by flash column chromatography . However , the firmed by presence of geminal hydrogens adjacent to the 
cyclobutanone product of overreduction was formed in ketone alpha ketone position at 8 3.33 and 2.94 by ' H - NMR 
significant amounts ( 28 % based upon ' H NMR and was and by the observation of eleven rather than twelve carbons 
nearly inseparable by flash column chromatography : IR 30 ( symmetry ) upon dechlorination to cyclobutanone 10 ) : 
( ZnSe , cm - 1 ) 2924 , 2854 , 1788 , 1735 , 1457 , 1161 , 733 , 696 R = 0.34 ( 10 % EtOAc / Hex ) ; IR ( ZnSe , cm ) : 2935 , 2852 , 
cm- ?; ' H NMR : 87.40-7.32 ( m , 5H ) , 5.113 / 5.110 ( overlap 1814 , 1730 , 905 , 725 cm - 1 ; ' H NMR : 8 7.39-7.29 ( m 5H ) , 
ping s , 2H ) , 4.95 ( dd , J = 3.1 , 9.4 , 0.3H ) , 4.37 ( dt , J = 2.7 , 7.8 5.12 ( s , 2H ) , 3.33 ( dd , J = 9.4 , 17.2 , Hz , 1H ) , 2.94 ( dd , .0 , 
Hz , 0.7H ) , 2.97-2.90 ( m , 0.3H ) , 2.84-2.74 ( m , 0.7H ) , 2.40 17.2 Hz , 1H ) , 2.88-2.81 ( m , 1H ) , 2.37 / 2.36 ( overlapping t , 
2.30 ( overlapping m , 2.3H ) , 2.08-1.97 ( m , 0.7H ) , 1.85-1.10 35 J = 7.5 Hz , 2H ) , 1.94-1.84 ( m , 1H ) , 1.70-1.72 ( m , 3H ) , 
( m , 26H ) , 0.92-0.84 ( m , 3H ) ; 13C NMR 8 204.6 , 202.0 , 1.46-1.28 ( m , 8H ) ; 13C NMR 8 192.8 , 173.4 , 136.0 , 128.4 , 
173.5 , 136.1 , 128.5 , 128.1 , 66.0 , 65.52 / 65.46 , 63.98 , 63.78 / 128.0 , 88.8 , 65.9 , 47.7 , 45.8 , 34.1 , 31.2 , 29.0 , 28.9 , 28.8 , 
63.75 , 63.57 / 63.52 , 60.74 / 60.69 , 49.8 , 43.7 , 37.4 , 36.63 / 27.2 , 24.7 ; HREI - MS : calcd . for C19H2503C12 : [ M + H ] * 
36.59 , 35.12 / 35.10 , 34.2 , 31.8 , 31.3 , 30.3 , 30.1 , 29.5 , 29.42 , 371.1181 . Found : 371.1188 . 
29.38 , 29.32 , 29.25 , 29.19 , 29.03 , 29.00 , 28.96 , 28.93 , 40 3- ( Octanoic acid , 8 - yl , benzyl ester ) 2,2 - dichlorocyclobu 
28.88 , 28.2 , 27.67 , 27.60 , 27.55 , 27.48 , 27.38 , 27.3 , 27.2 , tanol DA3 was prepared similarly to compound 0A3 from 
27.1 , 24.83 / 24.80 , 22.6 , 14.0 ; HRESI - MS : calcd . for the previous dichloroketone DA2 ( 10.0 g , 26.9 mmol ) , 
C27H4102C1Na , 471.2642 . Found [ M + Na ] * : 471.2630 . NaBH4 ( 1.528 g , 40.4 mmol ) , and iProH ( 350 mL ) . The 
2 - Chloro - 4 - octanoic acid , 8 - yl ) 3 - octylcyclobutanone- ; crude product was purified by flash column chromatography 
2 - Chloro - 3- ( octanoic acid , 8 - yl ) 4 - octylcyclobutanone ( 7 ) 45 with 10 % EtOAc / Hex to furnish the dichlorobutanol DA3 
was prepared similarly to compound 2. Reaction of benzyl ( 5.76 g , 57 % ) as a colorless oil : R = 0.39 ( 20 % EtoAc / Hex ) ; 
ester EA5 ( 0.0337 g , 0.11 mmol ) , with 10 % Pd / C ( 0.0236 g , IR ( ZnSe , cm- ? ) : 3440 ( br ) , 2927 , 2854 , 1733 , 1164 , 960 , 
0.022 mmol ) and EtoAc ( 1 mL ) afforded 0.0127 g of the 697 cm ' ; ' H NMR : 8 7.40-7.30 ( m 5H ) , 5.12 ( s , 2H ) , 
unprotected acid ( 54 % ) as a white solid : R = 0.24 ( 6 : 4 : 0.05 4.73-4.64 ( m , 0.1H ) 4.34-4.27 ( m , 0.9H ) , 2.97 ( d , J = 8.2 Hz , 
of Hex : EtOAc : AcOH ) ; mp . = 74-75 ° C .; IR ( ZnSe , cm ' ) 50 0.1H , OH is trans to backbone ) , 2.87 ( d , J = 10.3 Hz , 0.9H , 
3062 , 2924 , 2854 , 1789 , 1708 , 1464 cm - 1 ; ' H NMR : 8 8.70 OH is cis to backbone ) , 2.48-2.34 ( m , 1H ) , 2.36 ( t , J = 7.6 Hz , 
( br s , 1H ) , 4.95 ( dd , J = 2.9 , 9.2 , 0.3H ) , 4.37 ( ddd , J = 7.8 , 2.5 , 2H ) , 1.78-1.60 ( m , 3H ) , 1.53-1.28 ( m , 11H ) ; 13C NMR S 
1.3 , 0.7H ) , 2.97-2.91 ( m , 0.3H ) , 2.85-2.73 ( m , 0.7H ) , 2.40 173.7 , 136.0 , 128.5 , 128.1 , 92.9 , 75.4 , 66.1 , 45.6 , 34.5 , 34.2 , 
2.22 ( m , 22H ) , 2.11-2.98 ( m 0.7H ) , 1.85-1.10 ( m 26H ) , 29.8 , 29.2 , 29.0 , 28.9 , 26.5 , 24.8 ; HRESIMS : calcd . for 
0.92-0.82 ( m , 3H ) ; 13C NMR 8 211.7 , 204.7 , 202.2 , 179.9 , 55 C19H2302Cl2 : [ M + Na ] * 395.1157 . Found : 395.1151 . 
65.6 / 65.5 , 64.0 , 63.85 / 63.82 , 63.64 / 63.58 , 60.82 / 60.77 , 3- ( Octanoic acid , 8 - yl , benzyl ester ) 2,2 - dichlorocyclobu 
49.81 , 43.8 , 37.5 , 36.69 / 36.65 , 35.2 , 34.0 , 31.8 , 31.3 , 30.4 , tanol , methanesulfonate ester DA4 was prepared similarly to 
30.2 , 29.55 , 29.48 , 29.44 , 29.38 , 29.31 , 29.25 , 29.2 , 29.06 , compound OA4 from reaction of methanesulfonyl chloride 
29.06 , 28.9 , 28.3 , 28.2 , 27.73 , 27.67 , 27.62 , 27.44 , 27.37 , ( 20 mL , 29.4 mmol ) , cyclobutanol DA3 ( 5.50 g , 14.7 
27.26 , 27.20 , 27.17 , 24.63 / 24.60 , 22.7 , 14.1 ; HRESI - MS : 60 mmol ) , and triethylamine ( 9.2 mL , 66.3 mmol ) in CH C12 
calcd . for C20H350 , CIN , 381.2172 . Found [ M + Na ] * : ( 70 mL ) . The crude product was purified by flash chroma 
381.2170 . tography ( 10 % EtoAc / Hex ) to afford DA4 as a light yellow 
Benzyl 9 - decenoate ( DAI ) was prepared by a known oil ( 6.1340 g , 92 % ) : R = 0.36 ( 20 % Eto Ac / Hex ) ; IR ( ZnSe , 
procedure . ' Thionyl chloride ( 36.9 mL , 51 mmol ) was added cm- ? ) : 2927 , 2858 , 1731 , 1364 , 1179 , 952 cm- ' ; ' H NMR : 
to a stirred solution of 9 - decenoic acid DA ( 8.67 g , 51 mmol ) 65 87.36-7.31 ( m 5H ) , 5.11 ( s , 2H ) , 5.13-5.09 ( m , 1H ) , 3.18 ( s , 
and catalytic dimethylformamide ( DMF , 0.12 mL , 1.5 3H ) , 2.56-2.50 ( m , 2H ) , 2.35 ( t , J = 7.6 Hz , 2H ) , 1.93-1.28 
mmol ) in toluene ( 400 mL ) . The reaction was stirred at rt ( m , 13H ) ; 13C NMR 8 173.5 , 136.0 , 128.4 , 128.1 , 88.4 , 78.3 , 
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66.0 , 45.8 , 39.3 , 34.1 , 31.6 , 29.8 , 29.1 , 28.87 , 28.85 , 26.2 , were used to afford 0.0395 g ( 76 % ) of S15 ( a mixture of 9 : 1 
24.8 ; HRESI - MS : calcd . for C2H280 C1 , SNa : [ M + Na ] * of the stereoisomer , predominantly as the cis diastereomer 
473.0932 . Found : 473.0930 . based on previously assigned for cyclobutanol 4 ) as a 
8- ( 2 - Cyclobuten - 1 - yl ) -octanoic acid ( 8 ) was prepared by low - melting white solid : R = 0.29 ( 20 % EtOAc / Hex ) ; 
a similar procedure as 1 from reaction of Na metal ( 2.8 g , 5 m.p. = 30-31 ° C .; IR ( ZnSe , cm - 1 ) 3356 ( br ) , 2922 , 1734 , 
120 mmol ) with a solution of 5.4 g ( 12 mmol ) of the mixture 1154 , 735 , 696 cm- ?; ' H NMR : 8 7.40-7.30 ( m , 5H ) , 5.11 ( s , 
of dichloro mesylate DA4 in THF ( 30 mL ) and NH3 ( ~ 250 2H ) , 4.42-4.34 ( br m , 0.1H ) , 4.14-4.03 ( br m , 0.9H ) , 2.48 
mL ) . The crude product was purified by flash column 2.40 ( m , 0.18H ) , 2.35 ( t , J = 7.2 , 0.18H ) , 2.16-2.04 ( m , 0.2H ) , 
chromatography ( 2 % EtOAc / Hex ) to afford 9,10 - ethenooc 1.95 ( t , J = 6.6 , 0.2H ) , 1.70-1.56 ( br m , 3H ) , 1.48-1.13 ( br m , 
tadecanoic acid ( 1.6367 g , 52 % ) as a low - melting white 10 12H ) ; 13C NMR : 8 173.6 , 136.0 , 128.4 , 128.1 , 66.0 , 63.7 , 
solid : R = 0.47 ( 6 : 4 : 0.05 of Hex : EtOAc : AcOH ) ; m.p. = 20 39.7 , 37.0 , 34.2 , 29.2 , 29.1 , 29.0 , 27.3 , 25.4 , 24.82 ; HRCI 
21 ° C .; ÍR ( ZnSe , cm- ? ) 3112 ( br ) , 3043 , 2920 , 2853 , 1705 , MS : calcd . for C1 , H2,02Na [ M + Na ] " : 305.2117 . Found : 
697 cm ' ; ' H NMR : d 10.27 ( br s , 1H , COOH ) , 6.11 ( br d , 305.2116 . 
J = 2.4 Hz , 1H ) , 6.04 ( br dd , J = 0.8 , 2.0 Hz , 1H ) , 2.77 ( m , 1H ) , 3- ( Octanoic acid ) cyclobutanol ( 11 ) was prepared simi 
2.66 ( ddd , J = 0.8 , 4 , 13.2 Hz , 1H ) , 2.35 ( t , J = 7.2 Hz , 2H ) , 15 larly to compound 2. Benzyl ester DA6 ( 0.0337 g , 0.11 
2.04 ( d , J = 13.2 Hz , 1H ) , 1.64 ( quintet , J = 7.2 Hz , 2H ) , mmol ) , 10 % Pd / C ( 0.0236 g , 0.022 mmol ) and EtOAC ( 1 
1.51-1.38 ( br m , 2H ) , 1.38-1.23 ( br m , 8H ) ; 13C NMR 8 mL ) were used to afford 0.0127 g of the unprotected acid 11 
180.0 , 141.1 , 135.1 , 44.2 , 36.9 , 34.6 , 34.0 , 29.5 , 29.2 , 29.0 , ( 54 % ) as a white solid : R = 0.24 ( 6 : 4 : 0.05 of Hex : EtOAc : 
27.9 , 24.7 ; HRESI - MS : calcd . for C12H200 Na [ M + Na ] * : AcOH ) ; m.p. = 74-75 ° C .; IR ( ZnSe , cm- ? ) 3341 ( br ) , 2916 , 
219.1361 . Found : 219.1355 . Purity 100 % by HPLC ( reten- 20 2849 , 1695 , 1064 cm- ?; ' H NMR ( MOD ) : 8 4.30 ( quintet , 
tion time , 5.01 min ) . J = 6.8 , 0.1H ) , 4.01 ( quintet , J = 6.4 , 0.9H ) , 2.45-2.35 ( br m , 
8 - Cyclobutyloctanoic acid ( 9 ) was prepared by a similar 2H ) , 2.29 ( t , J = 7.2 , 2H ) , 1.75-1.55 ( br m , 3H ) , 1.50-1.15 ( br 
procedure as for 2 from the hydrogenation of cyclobutene 8 m , 12H ) ; 13C NMR ( MOD ) : 8 176.3 , 62.8 , 38.9 , 36.9 , 36.8 , 
( 0.0339 , 0.17 mmol ) , over 10 % Pd / C ( 0.0367 g , 0.03 mmol ) 33.6 , 29.1 , 29.0 , 28.8 , 27.1 , 25.4 , 24.7 ; HRESI - MS : calcd . 
in EtoAc ( 1.7 mL ) to afford 0.0301 g of the unprotected acid 25 for C12H2203Na [ M + Na ] * : 237.1467 . Found : 237.1460 . 
9 ( 89 % ) as a low - melting white solid : R -0.47 ( 6 : 4 : 0.05 of Purity > 97 % by HPLC ( retention time , 9.65 and 11.36 min ) . 
Hex : EtOAc : AcOH ) ; m.p. = 28-30 ° C .; IR ( ZnSe , cm- ? ) : 
3035 ( br ) , 2916 , 2849 , 1695 , 909 , 733 cm- ?; ' H NMR : 8 Example 2 – Determination of Inhibitor Aqueous 
11.34 ( br s , 1H , COOH ) , 2.37 ( t , J = 7.2 , 2H ) , 2.25 ( septet , Stability and Solubility 
J = 7.2 , 1H ) , 2.10-1.98 ( m , 2H ) , 1.90-1.75 ( m , 2H ) , 1.70-1.52 30 
( m , 2H ) , 1.40-1.12 ( br m , 10H ) ; 13C NMR : 8 180.3 , 37.0 , Although cyclobutenes are known to undergo thermally 
36.2 , 34.1 , 29.4 , 29.2 , 29.0 , 28.4 , 27.1 , 24.7 , 18.5 ; HRCI induced electrocyclic ring - opening , assessment of the ther 
MS : calcd . for C12H2202 : [ M + H ] * 199.1698 . Found : mal stability of cyclobutene using differential scanning 
199.1695 . Purity > 99 % by HPLC ( retention time , 4.92 min ) . calorimetry ( DSC ) and thermal gravimetric analysis ( TGA ) 
3- ( Octanoic acid benzyl ester , 8 - yl ) cyclobutanone ( DA5 ) 35 found no decomposition occurred at temperatures below 
was prepared similarly to oleate series . Dichloroketone DA2 150 ° C. ( FIG . 1 ) . 
( 1.05 g , 2.69 mmol ) , 6 mL of glacial acetic acid , and Zn ( Cu ) One - dimensional ( 1D ) ' H - NMR spectroscopy was used to 
26.9 mmol ) were used and the product was purified verify the chemical purity , aqueous stability , and concentra 
by flash chromatography ( 10 % EtOAc / Hex ) to afford col tion dependent micelle formation of eleven fatty acid ana 
orless oil 0.4859 g ( 59 % ) as a mixture of isomers : R 0.55 40 logs . Each compound was dissolved in deuterated dimethyl 
( 20 % EtOAc / Hex ) . IR ( ZnSe , cm - 1 ) 2923 , 2854 , 2780 , sulfoxide ( DMSO - do ) to obtain a stock concentration of 20 
2732 , 1163 , 730 , 697 cm - 1 ; ' H NMR : 8 7.35-7.28 ( br m , mM . Four different concentrations were prepared from the 
5H ) , 5.09 ( s , 2H ) , 3.13-3.03 ( m , 2H ) , 2.65-2.57 ( m , 2H ) , stock solutions for NMR analysis : 1.00 mm , 750 uM , 500 
2.33 ( t , J = 7.2 , 2H ) , 2.33-2.26 ( m , 1H ) , 1.68-1.58 ( br quintet , uM , 100 uM . All NMR samples consisted of 600 uL of a 
J = 6.4 , 2H ) , 1.58-1.48 ( br q , J = 7.2 , 2H ) , 1.29 ( br s , 8H ) ; 13C 45 deuterated 50 mM potassium phosphate buffer at pH 7.2 
NMR : 8 208.2 , 173.3 , 134.0 , 128.3 , 127.9 , 65.8 , 52.3 , 36.1 , with 50 uM of 3 ( trimethylsilyl ) propionic - 2,2,3,3 - d4 acid 
34.0 , 28.9 , 28.8 , 28.0 , 24.7 , 23.6 ; HRESI - MS : calcd . for sodium salt ( TMSP ) . Each 600 uL NMR sample contains 30 
C19H2603Na [ M + Na ] * : 325.1780 . Found : 325.1775 . uL ( 5 % ) of DMSO - do and was transferred to a 5 mm NMR 
3- ( Octanoic acid , 8 - yl ) cyclobutanone ( 10 ) was prepared tube for analysis . 
similarly to compound 2 : The benzyl ester DA5 ( 0.0346 , 0.1 50 A Bruker Avance DRX 500 - MHz spectrometer equipped 
mmol ) , 10 % Pd / C ( 0.020 g , 0.02 mmol ) and EtoAc 1 mL with a 5 mm triple - resonance cryoprobe ( ' H , 13C , 15N ) with 
were used and the product was purified by flash column a z - axis gradient was utilized for all 1D ' H NMR experi 
chromatography on silica gel ( step gradient of 20 % to 40 % ments . Acquisition of NMR spectra was automated using a 
EtOAc / Hex ) to afford 0.0189 g of the unprotected acid 10 BACS - 120 sample changer and Icon NMR software . All 
( 90 % ) as low - melting white solid : R -0.3 ( 6 : 4 : 0.05 of 55 spectra were acquired at 298.15 K with 16 dummy scans , 64 
Hex : EtOAc : AcOH ) ; m.p. = 35-37 ° C .; IR ( ZnSe , cm- ? ) 3094 scans , 32K data points , a spectral width of 5482.46 Hz , and 
( br ) , 2923 , 2853 , 1780 , 1705 cm- ?; ' H NMR : 8 10.61 ( br s , a relaxation delay of 1.5 s . The NMR spectra were processed 
1H , COOH ) , 3.17-3.08 ( m , 2H ) , 2.69-2.61 ( m , 2H ) , 2.35 ( br and analyzed using ACD / 1D NMR Manager ( Advanced 
t , J = 7.6 , 2H ) , 2.39-2.31 ( br , 1H ) , 1.69-1.53 ( br m , 4H ) , 1.32 Chemistry Development ) . The resulting 1D ' H NMR spec 
( br s , 8H ) ; 13C NMR : 8 208.8 , 179.9 , 52.5 , 36.3 , 34.0 , 29.2 , 60 tra were visually inspected for evidence of micelle formation 
29.1 , 28.9 , 28.2 , 24.6 , 23.8 ; HRCI - MS : calcd . for ( peak broadening ) , or chemical instability / impurities ( addi 
C12H2003Na , 213.1491 . Found [ M + Na ] * : 213.1490 . Purity tional peaks ) . 
> 97 % by HPLC ( retention time , 10.75 min ) . As exemplified in FIG . 2 , the results demonstrate the 
3- ( Octanoic acid benzyl ester ) cyclobutanol ( DA6 ) was analogs to be stable in aqueous buffer . The analogs based 
prepared similarly to reduction of compound OA6 : the 65 upon an octadecanoic acid ( 1 , 2 , 3 , 4 , 5 , 6 , and 7 ) scaffold 
mixed cyclobutanone DA5 ( 0.0509 g , 0.17 mmol ) in anhy aggregate at concentrations as low as 100 uM . The analogs 
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not form micelles or other aggregates at concentrations verify retrospectively the desired CFU / ml for each strain . 
below 1 mM , the measured MICs ( vida infra ) . Plates were incubated at 37 ° C. for 3-4 day ( M. smeg ) or 5-7 
weeks ( M. tb ) . MIC values were determined by the consis 
TABLE 1 tent results of three biological and three technical replicates . 
5 The MIC was defined by taking the mode of three indepen critical micellar coefficient ( CMC ) dent cultures where the MIC did not differ by more than one of analogs under assay conditions 
doubling dilution , discarding any results that are two dou 
CMC 21000 UM s100 UM bling dilutions away from the mode . 
Analogs 1 , 2 , 3 , 4 , 5 , 6 , 7 8 , 9 , 10 , 11 MICs were initially determined against M. Smeg ( mc2155 ) , a non - pathogenic mycobacteria used as a model 
Indicated concentration or range indicates onset of aggregation observed by ' H NMR of 
buffer solutions , see experimental for M. tb to analyze processes that are likely to be conserved 
in the genus , and against two M. tb strains ( CDC1551 and 
H37Rv ) . DSC , a clinically used TB drug , was employed as Example 3 — Measurement of Nonspecific a control since MIC determinations for this compound have Cytotoxicity been standardized numerous times under different condi 
RAW 264.7 macrophages were incubated with 0-100 UM tions in our laboratories . The analogs were added to wells as 
of oleic acid or the C18 cyclobutene fatty acid 1 , each solutions in DMSO - do ; the deuterated solvent was chosen 
delivered as bovine serum albumin complexes . After 24 h , for convenience to enable consistency with planned NMR cell viability was relative to untreated controls was assessed 20 based metabolomics studies . Importantly , the DMSO - do had 
using an IN CTYOTOX - CVDE Crystal violet Dye Elution no apparent effect on the growth of M. smeg , and contami 
Kit . nation was not evident in the compound stock control wells 
As illustrated in FIG . 4 , the cyclobutene analogue 1 or the media control wells . For M. tb , the combined analysis 
showed little toxicity at 50 uM and only modest toxicity at of 12 replicates for each of three independent cultures 100 „ M ; most naturally occurring fatty acids , represented 25 indicated no significant inhibition by DMSO - d , for either M. 
here by oleate , display some toxicity this cell line at con tb strain . Results for the fatty acid analogs are shown in 
centrations 2200 UM ( Russell , D. G. et al . , Science 2010 , Table 2 and FIG . 3. M. smeg was in general more resistant 
328 : 852-856 ; and McShane , H. , Trans . R. Soc . B 2011 , 366 , than M. tb to these analogs and DCS . The best MIC values 
2782-2789 ) . The low toxicity against a mammalian cell line against M. smeg were observed for 2 , the C18 - cyclobutanone supports the potential investigations into the modified fatty 30 ( 3 ) , 8 , and the C1o - cyclobutanol 11 , and were similar to the 
acids as potential antimicrobials . MIC for DCS ( 313 uM ) . Notably , four of the eleven mol ecules have MIC values < 100 uM for both M. tb strains : 
Example 4Bacterial Strains and Culture these include the C18 cyclobutane ( 2 ) , the C1o cyclobutene 
Conditions ( 8 ) , the C10 cyclobutane ( 9 ) , and the C18 cyclobutanol ( 4 ) . 
These MIC values were lower than that measured ( 122 uM ) 
Bacterial strains used in this study are M. smeg ( mc2155 ) for the second line antituberculosis drug D - cycloserine 
and two strains of M. tb ( CDC 1551 and H37Rv ) . Bacterial ( DCS ) . Four other analogs yielded lower MICs compared 
cells were grown with shaking at 37 ° C. in complete with DCS in M. tb H37Rv ; three others yielded higher MIC 
Middlebrook 7H9 broth supplemented with 0.05 % v / v values than DCS . 
Tween 80 to an OD600 of 0.6-1.2 . For MIC determinations , 40 
cells were inoculated into a modified previously reported TABLE 2 
minimal medium ( Chacon et al 2002 REF ) with components MIC values against M. smeg and M. tb and final concentrations as follows : 22 mM dibasic potas 
sium phosphate , 16 mM monobasic potassium phosphate , M. smeg ! ( mc2155 ) M. tbl ( CDC1551 ) . M. tbl ( H37Rv ) 
2.8x10-5 mM ferric chloride , 8.7x10-3 mM zinc sulfate , 45 MIC3 MICH MIC4 8.4x10-4 mM cobalt ( II ) chloride , 1.0x10-2 mM manganese molecule ? ( ug / ml ) ( UM ) ( ug / ml ) ( UM ) ( ug / ml ) ( UM ) chloride , 6.8x10-2 mM calcium chloride , 2.4 mM magne 
sium sulfate , 5.0 mM ammonium chloride , 25 mM glycerol , 
and 0.02 % v / v Tyloxapol . The use of minimal media was 
dictated by preliminary experiments indicating that standard 50 
complete Middlebrook 7H9 media components may inter 
fere with the MIC assay for some of these lipid analog 256 
compounds . 
35 




























































































For MIC testing , each fatty acid analog compound was 
suspended in 100 % DMSO - d , at either 100 mM ( M. smeg ) 
or 100 mg / ml ( M. smeg and M. tb ) . An equivalent concen 
tration DMSO - do was tested separately . The concentration 60 Utilized 3 biological replicates and 3 technical replicates ; 
gradients , expressed in ug / ml ( compound ) and % DMSO - da , All stocks are in 100 % hexadeutero dimethyl sulfoxide ( DMSO - d6 ) ; 
3The highest concentration tested was 1024 ug / ml ; were generated using a power - 2 series and varied between The highest concentration tested was 256 ug / ml experiments . MICS determined by a 96 - well 
microplate twofold dilution method . Bacteria were har The MIC results demonstrate promising levels of inhibi 
vested , washed 2x with minimal media , and inoculated to an 65 tion with a variety of four - membered ring carbocycles 
initial concentration of approximately 1.0x105 colony form ( cyclobutanol , cyclobutanone , cyclobutene , and cyclobu 
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against M. tb H37Rv and more than thirty fold against strain halo , CN , NO , ORI , SRal , C ( O ) Rbi , c ( 0 ) 
CDC1551 ; a much smaller range is observed against M. NRCRI , C ( O ORI , OC ( O ) RÓI , OC ( O ) NRCRAI , 
smeg . Moreover , the nature of the functionality clearly has CENRel ) NRCIRd1 , NRC NRENRCRDI , 
an impact on activity . The different influences of function NRCIRPI , NRC (O ) R51 , NRC ( O ) ORI , NRC 
ality within the C18 and C10 series are also notable ; for 5 ( O ) NRCIR ( I , NRCIS ( O ) RI , NR S ( O ) , R ” 1 , NRCIS 
example , the short - chain cyclobutanone ( 10 ) and cyclobu ( O ) , NRCRai , S ( O ) RbI S ( O ) NRIRT s 0 ) R1 ,tanol ( 11 ) are less potent toward mycobacteria than the S ( O ) 2NR IRdl and oxo ; corresponding long - chain analogs ( 3 and 4 ) , while the each Ral , Rb1 , R1 , Rdl , is independently selected from opposite trend is observed with the cyclobutenes ( 8 vs. 1 or C1-4 haloalkyl , C2-6 alkenyl , C2-6 alkynyl , C6-10 aryl , 6 ) or cyclobutanes ( 9 vs. 2 or 7 ) . The cis / trans configuration 10 
of the four - membered carbocycle ( monochlorocyclobu C3-10 carbocyclyl , 5-10 membered heteroaryl , 4-10 membered heterocyclyl , C6-10 aryl - C1-4 alkyl , C3-10 tanones 5 vs. 7 ) appears to have a substantial influence on 
MICs for M. tb . ( H37Rv ) ; however , no different is observed carbocyclyl - C1-4 alkyl , ( 5-10 membered heteroaryl ) 
for cyclobutenes 1 and 6 . C1-4 alkyl or ( 4-10 membered heterocyclyl ) -C1-4 alkyl , wherein said C26 alkenyl , C2-6 alkynyl , C6-10 Most of our analogs ( 8 out of 11 ) show lower MIC values 15 
in M. tb than M. smeg . The five to ten fold differences aryl , C3-10 carbocyclyl , 5-10 membered heteroaryl , 
between MICs for M. smeg and M. tb with some analogs ( 2 , 4-10 membered heterocyclyl , C6-10 aryl - C1-4 alkyl , 
4 , 6 , 8 and 9 ) may result from a mechanism of action specific C3-10 carbocyclyl - C - 4 alkyl , ( 5-10 membered het 
to M. tb . Isoniazid , for example , demonstrates 100 - fold eroaryl ) -C1-4 alkyl and ( 4-10 membered heterocy 
more potent inhibition of M. tb compared with M. smeg and 20 clyl ) -C1-4 alkyl is optionally substituted with 1 , 2 , 3 , 
possesses no toxicity toward other mycobacteria and pro 4 , or 5 substituents independently selected from C1-4 
karyotic pathogens . The influence of the analogs may be alkyl , C1-4 haloalkyl , halo , CN , OR04 , SR04 , C ( O ) 
specific to a metabolic pathway only found in M. tb such as Rb4 , CONR + Rd4 , C ( O ) ORC4 , OC ( O ) Rb4 , OC ( O ) 
at the final elongation step . It is also possible that our NRC4Rd4 NR4Rd4 , NRC4C ( O ) Rb4 , NRC4C ( O ) NR4R04 four - membered ring analogs are converted into analogs of 25 NR 4C ( O ) OR 44 CNR 4 ) NR * R44 
mycolic acids and that the physical properties of these NRCACE = NR24 ) NRC4Rd4 , S ( O ) Rb4 , S ( O ) NR + Rd 
unnatural cell wall constituents results in cell death . S ( O ) 2Rb4 NRCS ( O ) , Rb4 , NRCAS ( O ) 2NR “ Rd4 and S ( O ) NR + Rd4 
Other Embodiments each Ra4 , R64 , RC4 and Rd4 is independently selected 
from H , C1-4 alkyl , C1-4 haloalkyl , C2-4 alkenyl and 
It is to be understood that while the invention has been C2-4 alkynyl , wherein said C - 4 alkyl , C2-4 alkenyl , 
described in conjunction with the detailed description and C2-4 alkynyl , is optionally substituted with 1 , 2 , 
thereof , the foregoing description is intended to illustrate or 3 substituents independently selected from OH , 
and not limit the scope of the invention , which is defined by CN , amino , halo , C1-4 alkyl , C1-4 alkoxy , C1-4 alky 
the scope of the appended claims . Other aspects , advantages , 35 Ithio , C - 4 alkylamino , di ( C - 4 alkyl ) amino , C1-4 
and modifications are within the scope of the following haloalkyl , and C -4 haloalkoxy ; and 
claims . Z is selected from the group consisting of : COR , COZH , 
NHC ( O ) NRÖR ?, CONR , OCOR , ORÓ , SR “ , NROR , 
What is claimed is : and OPO , Rº , 
1. A compound of Formula ( I ) : Ris C - C6 alkyl ; 
R? and R ’ are independently H or C - C . alkyl ; and 
wherein the hydrocarbon backbone formed by R4 and 
R ! R3 - Z is amphiphilic . 
2. The compound of claim 1 , wherein R and R² are 
independently selected from the group consisting of : H , 
halo , and —O . 
R4 R3 — Z 3. The compound of claim 1 , wherein the compound is 
selected from the group consisting of : 
or a pharmaceutically acceptable salt thereof , 
wherein : 
represents an optionally present double bond ; 
R and R2 are independently selected from the group 
consisting of : H , halo , OR® , and = 0 ; 
R? is an optionally substituted C3 - C40 alkyl ; R3 — Z R4 R3 — Z R4 R3 — Z R * is C2 - C30 alkyl optionally substituted with Cy ' , C1-6 55 
alkyl , C2-6 alkenyl , C2-6 alkynyl , halo , C1-6 haloalkyl , 
CN , NO2 , ORCI , SRAT , C ( O ) RI , C ( O ) NRCIRDI , C ( O ) 
ORI , OC ( O ) NRRdi , Ce = NR ) NRCIR'I , NRC 
ENRI )NRCRI , NRIRI , NRCÍC ( ORI , NRCIC R3 - Z 
OOR NRICONRRI , NR ISORI , NRCS 60 CI 
( O ) Rb1 , NRCIS ( O ) 2NRCIRDI , S ( O ) RbI , S ( O ) NRCIRd1 
S ( O ) 2Rb1 and S ( O ) 2NRCIR'I ; each Cylis independently C - 10 aryl , Cz.10 carbocyclyl , 
R4 R3 — Z R4 R3 - Z 5-10 membered heteroaryl or 4-10 membered het 
erocyclyl , each of which is unsubstituted or substi- 65 
tuted by 1 , 2 , 3 , 4 or 5 substituents independently or a pharmaceutically acceptable salt thereof . 
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5. The compound of claim 1 , wherein Z is CO2H . 
6. The compound of claim 1 , wherein the compound is a 
compound of Formula ( II ) : 
-continued CI XX 5 CgHìg ( CH2 ) 7CO2H C8H18 ( CH2 ) 7CO2H R ! R2 
poll . 
or a pharmaceutically acceptable salt thereof . 
10. A pharmaceutical composition comprising a com 
pound of Formula ( I ) : R3 - Z 10 
R ! R2 or a pharmaceutically acceptable salt thereof . 
7. The compound of claim 1 , wherein the compound is a 




R4 R3 — Z 
25 or a pharmaceutically acceptable salt thereof . 
8. The compound of claim 1 , wherein the compound is 
selected from the group consisting of : 
30 
C8H18 ( CH2 ) 7CO2H C3H18 ( CH2 ) 7CO2H 
O 
35 
C8H18 ( CH2 ) 7CO2H C8H18 ( CH2 ) 7CO2H 
CI 
40 
C8H18 ( CH2 ) 7CO2H C8H18 ( CH2 ) 7CO2H 
or a pharmaceutically acceptable salt thereof , 
wherein : 
represents an optionally present double bond ; 
R and R2 are independently selected from the group 
consisting of : H , halo , OR , and = 0 ; 
R is an optionally substituted C3 - C40 alkyl ; 
R * is C - C40 alkyl optionally substituted with Cy ?, C1-6 
alkyl , C2-6 alkenyl , C2-6 alkynyl , halo , C1-6 haloalkyl , 
CN , NO2 , ORCI , SRT , C ( O ) RI , C ( O ) NRCIRI , CO ) OR , OC ( O ) NRCI Rdí , CNRI )NRCIRDI , NRCI? ENRI ) NRCRDI , NRCRI , NR - C ( ORI , NRC 
( O ) ORI , NRIC ( O NRCRAI , NRCIS ( O ) RÞI , NRCIS 
( O ) , R " !, NRCIS ( O ) 2NRCROI , S ( O ) R1 , S ( O ) NR Irdi 
S ( O ) , R51 and S ( O ) , NR Rdi 
each Cyl is independently C6-10 aryl , C3-10 carbocyclyl , 
5-10 membered heteroaryl or 4-10 membered het 
erocyclyl , each of which is unsubstituted or substi 
tuted by 1 , 2 , 3 , 4 or 5 substituents independently 
selected from C1-6 alkyl , C2-6 alkenyl , C2-6 alkynyl , 
halo , CN , NO , ORCI , SRal , C ( O ) RI , C ( O ) 
NRCRai , ' C ( O Oral , OC ( O ) Rbi , OC ( O ) NR Ral 
CENREINRIRI , NRCICE NR NR Rd 
NRC'RI , NRC C ( O ) R01 , NR C ( O ) Orál , NRIC 
( O ) NRCIR'I , NRC?S ( O ) R " , NRCIS ( O ) , R " Í , NRCIS 
( O ) NRCIR “ , s ( o ) RÍ , S ( O ) NRCIRT , s ( 0 ) R " , 
S ( O ) 2NR Rd and oxo ; 
each Ral , RbI , RCI , Rdl , is independently selected from 
Chaloalkyl , C2 . alkenyl , C2-6 alkynyl , C6-10 aryl , 
C3-10 carbocyclyl , 5-10 membered heteroaryl , 4-10 
membered heterocyclyl , C6-10 aryl - C1-4 alkyl , C3-10 
carbocyclyl - C1-4 alkyl , ( 5-10 membered heteroaryl ) 
C1-4 alkyl or ( 4-10 membered heterocyclyl ) -C1-4 
alkyl , wherein said C2 6 alkenyl , C2-6 alkynyl , C6-10 
aryl , C3-10 carbocyclyl , 5-10 membered heteroaryl , 
4-10 membered heterocyclyl , C6-10 aryl - C -4 alkyl , 
C3-10 carbocyclyl - C - 4 alkyl , ( 5-10 membered het 
eroaryl ) -C -4 alkyl and ( 4-10 membered heterocy 
clyl ) -C1-4 alkyl is optionally substituted with 1 , 2 , 3 , 
4 , or 5 substituents independently selected from C1-4 
alkyl , C1-4 haloalkyl , halo , CN , OR04 , SR04 , C ( O ) 
Rb4 , C ( O ) NR Rd4 , C ( O ) ORC4 , OC ( O ) Rb4 , OC ( O ) 
NRC4Rd4 , NR4R04 , NRCAC ( O ) Rb4 , NRC4C ( O ) 
NR - Rd4 NRC4C ( O ) OR44 CNR 4 NRRd4 
NRC4CNR 4 ) NR + Rd4 S ( O ) Rb4 , S ( O ) NR + Rd 
S ( O ) 2Rb4 NRCS ( O ) Rb4 , NRC4S ( O ) 2NR “ Rd4 and 
S ( O ) NR - Rd4 
each Ra4 , Rb4 , RC4 and Rd4 is independently selected from 
H , C1-4 alkyl , C1-4 haloalkyl , C2-4 alkenyl and C2-4 
45 or a pharmaceutically acceptable salt thereof . 
9. The compound of claim 8 , wherein the compound is 
selected from the group consisting of : 
50 
CgHj8 ( CH2 ) 7CO2H C3H18 ( CH2 ) 7CO2H 
55 
C3H18 ( CH2 ) 7CO2H CgHj8 ( CH2 ) 7CO2H 
60 
C8H8 C2H18 ( CH2 ) 7CO2H 
O 
( CH2 ) 7CO2H 
CI 
d4 X 65 C3H18 ( CH2 ) 7C02H C2H18 ( CH2 ) 7CO2H 
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alkynyl , wherein said C1-4 alkyl , C2-4 alkenyl , and C2-4 chelonae , Mycobacterium bolletti , Mycobacterium fortui 
alkynyl , is optionally substituted with 1 , 2 , or 3 sub tum clade , Mycobacterium parafortuitum clade , Mycobac 
stituents independently selected from OH , CN , amino , terium vaccae clade , and CF. 
halo , C1-4 alkyl , C1-4 alkoxy , C1-4 alkylthio , C1-4 alky 13. The method of claim 11 , wherein the mycobacterial 
lamino , di ( C - 4 alkyl ) amino , C - 4 haloalkyl , and C -4 5 infection is M. tuberculosis . 
haloalkoxy ; and 14. The compound of claim 1 , wherein R4 is a C3 - C20 Z is selected from the group consisting of : COR ” , CO H , alkyl . CONRÓ , OCOR , ORÓ , SR “ , NRÖR ?, and OPOZR " ; 
R $ is C -Co alkyl ; 15. The compound of claim 1 , wherein R4 is a C10 - C30 
R and R7 are independently H or C.-C. alkyl ; and alkyl . 
wherein the hydrocarbon backbone formed by R4 and 16. The compound of claim 1 , wherein R * is a C2 - C , alkyl . 
R - Z is amphiphilic 17. The compound of claim 1 , wherein R4 is a Cg alkyl . 
and a pharmaceutically acceptable carrier . 18. A compound selected from the group consisting of : 
11. A method for treating a mycobacterial infection in a 
patient , the method comprising administering to the patient 15 
a therapeutically effective amount of a compound of For ?? 
mula ( I ) : 
10 
HO 
C3H18 C3H18 ( CH2 ) 7CO2H R ! R2 20 * ( CH2 ) 7CO2H 
?? . 
R4 R3 - Z ( CH2 ) 7CO2H ( CH2 ) 7CO2H 
25 
( CH2 ) 7CO2H " ( CH2 ) 7CO2H 
OH ?? . 
30 
CH 18 ( CH2 ) 7C02H C8H18 
HO 
( CH2 ) 7CO2H 
35 
or a pharmaceutically acceptable salt thereof , 
wherein : 
represents an optionally present double bond ; 
R ! and R² are independently selected from the group 
consisting of : H , halo , OR ” , and = 0 ; 
R3 is absent or is an optionally substituted C , -C40 alkyl ; 
R * is H or an optionally substituted C. - C40 alkyl ; and 
Z is selected from the group consisting of : COR ” , CO2R “ , 
CONR , OCOR , OR , SR , NR R ?, and OPOZR ; 
R is H or C.-C. alkyl ; 
R? and R ’ are independently H or C.-C. alkyl ; 
wherein the backbone formed by R + and R3Z is amphi 
philic 
12. The method of claim 11 , wherein the mycobacterial 
infection is a member of a group selected from : Mycobac- 40 
terium tuberculosis complex ( MTBC ) , Mycobacterium 
avium complex ( MAC ) , Mycobacterium gordonae clade , 
Mycobacterium kansasii clade , Mycobacterium nonchro mogenicum / terrae clade , Mycolactone - producing mycobac 
teria , Mycobacterium simiae clade , Mycobacterium che- 45 
lonae clade , Mycobacterium abscessus , Mycobacterium 
( CH2 ) 7CO2H ( CH2 )7CO2H 
( CH2 ) 7CO2H ( CH2 ) 7CO2H 
or a pharmaceutically acceptable salt thereof . 
